UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.  )

Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

  

Preliminary Proxy Statement

  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

  

Definitive Proxy Statement

  

Definitive Additional Materials

  

Soliciting Material Pursuant to §240.14a-12

Sonida Senior Living, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

  

No fee required.

  

Fee paid previously with preliminary materials.

  

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


SONIDA SENIOR LIVING, INC.

16301 QUORUM DRIVE,14755 PRESTON ROAD, SUITE 160A810

ADDISON,DALLAS, TEXAS 7500175254

NOTICE OF ANNUALSPECIAL MEETING OF STOCKHOLDERS

To Be Held June 9, 2022March 21, 2024

To the Stockholders of Sonida Senior Living, Inc.:

NOTICE IS HEREBY GIVEN that the Annuala Special Meeting of Stockholders (the “Annual Meeting”) of Sonida Senior Living, Inc., a Delaware corporation (the “Company”), will be held at the RenaissanceCompany’s Corporate Office at 14755 Preston Road, Suite 810, Dallas, Texas 75254, on March 21, 2024 at Plano Legacy West Hotel, Tokyo Conference Room, at 6007 Legacy Drive, Plano, Texas 75204, on the 9th day of June, 2022 at 9:3:00 a.m.p.m. Central Time for the following purposes:(the “Special Meeting”) to consider and vote on proposals to approve:

1. To elect three directorsAn amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 15,000,000 shares to 30,000,000 shares; and

2. The adjournment of the Company to hold office until the AnnualSpecial Meeting to be held in 2025 or until their respective successorssolicit additional proxies if there are duly qualified and elected;insufficient proxies at the Special Meeting to approve the foregoing proposal.

2. To ratify the Audit Committee’s appointment of RSM US LLP, independent accountants, asThe proposed amendment to the Company’s independent auditors for the fiscal year ending December 31, 2022;

3. To cast an advisory vote on executive compensation;Amended and

4. To transact any and all other business that may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.

These proposals are Restated Certificate of Incorporation, as amended, is described in more detail in the Company’saccompanying Proxy Statement.

Our Board of Directors unanimously approved the proposals and recommends that our stockholders vote

“FOR” each of the proposals.

The Board of Directors has fixed the close of business on April 18, 2022February 12, 2024 as the record date (the “Record Date”) for the determination of stockholders entitled to notice of and to vote at the AnnualSpecial Meeting or any adjournment(s) or postponement(s) thereof. Only holders of record at the close of business on the Record Date of shares of the Company’s common stock and Series A Convertible Preferred Stock are entitled to notice of and to vote at the AnnualSpecial Meeting. The stock transfer books will not be closed. A list of stockholders entitled to vote at the AnnualSpecial Meeting will be available for examination at the Company’s principal executive offices located at 14755 Preston Road, Suite 810, Dallas, Texas 75254 for ten days prior to the AnnualSpecial Meeting.

You are cordially invited to attend the AnnualSpecial Meeting; however, whether or not you expect to attend the AnnualSpecial Meeting in person, you are urged to mark, sign, date and mail the enclosed proxy card promptly so that your shares of stock may be represented and voted in accordance with your preferences and in order to help establish the presence of a quorum at the AnnualSpecial Meeting. If you attend the AnnualSpecial Meeting and would like to vote in person, you may do so even if you have already dated, signed and returned your proxy card.

Please note that, although we currently intend to hold the Annual Meeting in person, we are actively monitoring the health and safety concerns and government recommendations and restrictions relating to the novel coronavirus (COVID-19). As a result, in the event we determine that it is advisable to hold the Annual Meeting partly or solely by means of virtual communications, we will publicly announce such alternative arrangements as promptly as practicable before the Annual Meeting. We will announce any decision to modify the structure of the Annual Meeting, along with details on how to participate, by press release (which will be available on our website at www.sonidaseniorliving.com/investor-relations) and a filing with the SEC. If you are planning to attend the Annual Meeting, please be sure to check our website and SEC filings for any updates prior to the Annual Meeting. As always, we encourage you to vote your shares prior to the Annual Meeting.

Pursuant to the rules of the New York Stock Exchange, if you hold your shares in street name, brokers, banks or other nominees will not have discretion to vote your shares on the election of directors and the advisory vote on executive compensation.without instructions from you. We encourage you to provide voting instructions to your broker, bank or other nominee if you hold your shares in street name so that your voice is heard on such matters.


Important Notice Regarding Availability of Proxy Materials for the Stockholders Meeting to be held on June 9, 2022:March 21, 2024: The Company’s Proxy Statement and the 2021 Annual Report to Stockholders areis also available at www.proxydocs.com/snda.

By Order of the Board of Directors

 

LOGO  LOGO

LOGO

David W. Johnson

Chairman of the Board

  

Kimberly S. Lody

Brandon M. Ribar

President and Chief Executive Officer

April 29, 2022February [●], 2024

Addison,Dallas, Texas


TABLE OF CONTENTS

Page

PRINCIPAL STOCKHOLDERS AND STOCK OWNERSHIP OF MANAGEMENT

5

ELECTION OF DIRECTORS (PROPOSAL 1)

8

BOARD OF DIRECTORS AND COMMITTEES

12

EXECUTIVE OFFICERS

20

EXECUTIVE COMPENSATION TABLES

22

2021 DIRECTOR COMPENSATION

29

CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

31

PROPOSAL TO RATIFY APPOINTMENT OF INDEPENDENT AUDITORS (PROPOSAL 2)

32

FEES PAID TO INDEPENDENT AUDITORS

33

ADVISORY VOTE ON EXECUTIVE COMPENSATION (PROPOSAL 3)

34

OTHER BUSINESS (PROPOSAL 4)

36

GENERAL

36


SONIDA SENIOR LIVING, INC.

16301 Quorum Drive,14755 Preston Road, Suite 160A810

Addison,Dallas, Texas 7500175254

PROXY STATEMENT FOR ANNUALTHE SPECIAL MEETING OF STOCKHOLDERS

To Be Held June 9, 2022March 21, 2024

Solicitation and Revocability of ProxiesSOLICITATION OF PROXIES BY BOARD OF DIRECTORS

The Board of Directors (the “Board of Directors” or the “Board”) of Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our” or “us”) is soliciting your proxy for voting on the proposals to be presented at our annualspecial meeting of our stockholders to be held on June 9, 2022March 21, 2024 (the “Annual“Special Meeting”). The AnnualSpecial Meeting will be held at the RenaissanceCompany’s Corporate Office at 14755 Preston Road, Suite 810, Dallas, at Plano Legacy West Hotel, Tokyo Conference Room, at 6007 Legacy Drive, Plano, Texas 7520475254 on the 9th21st day of June, 2022March, 2024 at 9:3:00 a.m.p.m. Central Time for the purposes set forth in the accompanying noticeNotice of Special Meeting of Stockholders and described in this Proxy Statement. When proxies in the accompanying form are properly executed and received, the shares represented thereby will be voted at the AnnualSpecial Meeting in accordance with the directions noted thereon, unless the proxy is subsequently revoked.

Please note that, although we currently intend to hold the Annual Meeting in person, we are actively monitoring the health and safety concerns and government recommendations and restrictions relating to the novel coronavirus (COVID-19). As a result, in the event we determine that it is advisable to hold the Annual Meeting partly or solely by means of virtual communications, we will publicly announce such alternative arrangements as promptly as practicable before the Annual Meeting. We will announce any decision to modify the structure of the Annual Meeting, along with details on how to participate, by press release (which will be available on our website at www.sonidaseniorliving.com/investor-relations) and a filing with the Securities and Exchange Commission (“SEC”). If you are planning to attend the Annual Meeting, please be sure to check our website and SEC filings for any updates prior to the Annual Meeting. As always, we encourage you to vote your shares prior to the Annual Meeting.QUESTIONS AND ANSWERS

Any stockholder giving a proxy has the unconditional right to revoke his or her proxy at any time prior to the voting thereof by attending the Annual Meeting and voting in person at the Annual Meeting, by delivering a duly executed proxy bearing a later date or by giving written notice of revocation to us addressed to David R. Brickman, Senior Vice President, General Counsel and Secretary, 16301 Quorum Drive, Suite 160A, Addison, Texas 75001. However, no such revocation will be effective unless such notice of revocation has been received by us at or prior to the Annual Meeting.ABOUT THESE PROXY MATERIALS AND THE SPECIAL MEETING

Our principal executive offices are located at, and our mailing address is, 16301 Quorum Drive, Suite 160A, Addison, Texas 75001.

Our management does not intend to present any business at the Annual Meeting for a vote other than the matters set forth in the accompanying notice and described in this Proxy Statement and has no knowledge that others will do so. If other matters requiring a vote of our stockholders properly come before the Annual Meeting, then it is the intention of the persons named in the accompanying form of proxy to vote the shares represented by the proxies held by them in accordance with their judgment on such matters.

This Proxy Statement and accompanying form of proxy are being mailed on or about April 29, 2022. Our Annual Report to our stockholders covering our fiscal year ended December 31, 2021, which was mailed to our stockholders on or about April 29, 2022, does not form any part of the materials for solicitation of proxies.

In addition to the solicitation of proxies by mail, our officers, directors and employees may solicit proxies by telephone, telecopy, email or through personal contact. Such officers, directors and employees will not be additionally compensated by us but will be reimbursed for any out-of-pocket expenses. We have retained

Georgeson Communications Inc. to assist in the solicitation of proxies for a fee of $8,500. This amount includes fees payable to Georgeson, but excludes salaries and expenses of our officers, directors and employees. Brokerage houses and other custodians, nominees and fiduciaries will, in connection with shares of our common stock registered in their names, be requested to forward solicitation material to the beneficial owners of such shares of our common stock.Why am I receiving these materials?

The cost of preparing, printing, assembling and mailing our annual report, the accompanying notice,Company sent you this Proxy Statement and the enclosed form of proxy as well ascard because the reasonable cost of forwarding solicitation materialsBoard is soliciting your proxy to consider and vote at the Special Meeting to approve (1) an amendment to the beneficial owners of shares of our stock, and other costs of solicitation, will be exclusively borne by us.

Some banks, brokers and other record holders have begun the practice of “householding” proxy statements and annual reports. “Householding” is the term used to describe the practice of delivering a single copy of this Proxy Statement and our Annual Report to any household at which two or more stockholders share an address. This procedure would reduce the volume of duplicative information and our printing and mailing costs. We will deliver promptly, upon written or oral request, a separate copy of this Proxy Statement and our Annual Report to any stockholder at a shared address to which a single copy of such documents was delivered. Any stockholder who would like to receive a separate copy of this Proxy Statement and our Annual Report, now or in the future, should submit this request to David R. Brickman, Senior Vice President, General Counsel and Secretary, at our principal executive offices, 16301 Quorum Drive, Suite 160A, Addison, Texas 75001 or by calling (972) 770-5600. Beneficial owners sharing an address who receive multiple copies of this Proxy Statement and our Annual Report and who would like to receive a single copy of such proxy materials in the future will need to contact their broker, bank or other nominee to request that only a single copy of each document be mailed to all stockholders at the shared address in the future.

Date for Receipt of Stockholder Proposals

Stockholder proposals to be included in the proxy statement for the 2023 annual meeting of our stockholders must be received by us at our principal executive offices on or before December 30, 2022 for inclusion in the proxy statement relating to that meeting.

OurCompany’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), establishes an advance notice procedureto increase the number of authorized shares of common stock from 15,000,000 shares to 30,000,000 shares (the “Charter Amendment Proposal”); and (2) the adjournment of the Special Meeting to solicit additional proxies if there are insufficient proxies at the Special Meeting to approve the foregoing proposal (the “Adjournment Proposal,” together with regard to certain matters, including stockholder proposals and nominationsthe Charter Amendment Proposal, the “Meeting Proposals”).

What is the purpose of individuals for election to the Board, to be proposed at an annual meetingSpecial Meeting?

At the Special Meeting, holders of our stockholders. Notice of a stockholder proposal or a director nominationcommon stock and Series A Convertible Preferred Stock will be asked to be brought at an annual meeting of our stockholders must be delivered to, or mailedconsider and received at, our principal executive offices not less than 60 but not more than 90 days before the scheduled date of the meeting, regardless of any postponement, deferral or adjournment of that meeting to a later date; provided, however, that if less than 70 days’ notice or prior public disclosure of the date of the meeting is given or made to stockholders, the notice must be delivered or received no later than the close of businessvote on the tenth day followingCharter Amendment Proposal and the earlier of (1)Adjournment Proposal if there are insufficient proxies at the day on which such notice ofSpecial Meeting to approve the date of meeting was mailed or (2)Charter Amendment Proposal.

Who is entitled to vote at the day on which such public disclosure was made. The notice of a stockholder proposal or a director nomination must also contain specified information and conform to certain requirements set forth in our Certificate of Incorporation. The chairman of the meeting may disregard the introduction of any such proposal or nomination if it is not made in compliance with the foregoing procedures or the applicable provisions of our Certificate of Incorporation.

Quorum and VotingSpecial Meeting?

Only holders of record at the close of business on April 18, 2022February 12, 2024 (the “Record Date”) of shares of our common stock and Series A Convertible Preferred Stock are entitled to notice of and to vote at the AnnualSpecial Meeting. As of the Record Date, there were (i) 6,755,938[11,528,724] shares of our common stock issued and outstanding,

and (ii) 41,250 shares of Series A Convertible Preferred Stock issued and outstanding, which wereare convertible into 1,031,250[1,229,311] shares of our common stock and are entitled to an aggregate of 1,031,250[1,229,311] votes on the proposals described in this Proxy Statement.

Why is the Company seeking approval of the Charter Amendment Proposal?

Our Certificate of Incorporation currently allows us to issue up to 15,000,000 shares of common stock, par value $0.01 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share. As of the Record Date, there were (i) [11,528,724] shares of common stock issued and outstanding, (ii) 41,250 shares of Series A Convertible Preferred Stock issued and outstanding, which are convertible into an additional [1,229,311] shares of our common stock, (iii) 1,031,250 additional shares of common stock issuable upon the exercise of outstanding warrants, (iv) 350,000 additional shares of common stock issuable pursuant to our equity

1


commitment agreement with affiliates of Conversant Capital, LLC (“Conversant”), (v) 601,617 additional shares of common stock available for issuance pursuant to our 2019 Omnibus Stock and Incentive Plan, as amended (the “2019 Plan”), and (vi) 23,370 additional shares of common stock issuable upon exercise of outstanding stock options or settlement of RSUs. As a result, as of the Record Date the total number of shares of our common stock issuable on a fully diluted basis and after giving effect to the shares reserved for issuance under the 2019 Plan is approximately [14,764,272] shares, resulting in [235,728] shares available for future issuances.

As previously announced, on February 1, 2024 we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Conversant Parkway (A) LP (“Conversant A”), Conversant Parkway (B) LP (“Conversant B” and, together with Conversant A, “Conversant”), PF Investors, LLC (“PF Investors”), Silk Partners, LP (“Silk Partners” and, together with PF Investors, “Silk”), Paul J. Isaac (“Isaac”), Solas Capital Partners, LP (“Solas I”), Solas Capital Partners II, LP (“Solas II”), and Blackwell Partners LLC—Series A (“Blackwell” and, together with Solas I and Solas II, “Solas” and, collectively, Conversant, Silk, Isaac and Solas, the “Purchasers”), pursuant to which the Purchasers agreed to purchase from us, and we agreed to sell to the Purchasers, in a private placement transaction (the “Private Placement”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), an aggregate of 5,026,318 shares (the “Shares”) of our common stock, at a price of $9.50 per share. The Private Placement will occur in two closings. At the first closing, which was completed on February 1, 2024, we issued and sold an aggregate of 3,350,878 Shares to the Purchasers and received gross cash proceeds of $31,833,341. At the second closing, which is anticipated to occur on or around March 31, 2024, we will issue the remaining 1,675,440 Shares to the Purchasers and receive additional gross cash proceeds of $15,916,680. As indicated above, after giving effect to the shares of our common stock that are outstanding and reserved for issuance, we currently do not have a sufficient number of shares of authorized and unissued common stock to complete the second closing of the Private Placement. Accordingly, the second closing is subject to our stockholders approving the Charter Amendment Proposal (in addition to other customary closing conditions) and the Securities Purchase Agreement provides that we will use our reasonable best efforts to obtain stockholder approval of the Charter Amendment Proposal at a meeting of the Company’s stockholders no later than April 30, 2024. Each Purchaser has also agreed to vote all voting securities of the Company owned or controlled by such Purchaser in favor of the Charter Amendment Proposal. We are seeking approval of the Charter Amendment Proposal at this time to satisfy our obligations under the Securities Purchase Agreement, consummate the second closing of the Private Placement and provide us with flexibility to issue additional shares of common stock in the future.

Please refer to “Amendment to the Company’s Certificate of Incorporation (Proposal 1)—Purposes of the Charter Amendment” below for more information.

How does the Board recommend that I vote on the Meeting Proposals?

The Board of Directors unanimously recommends that you vote “FOR” each of the Meeting Proposals. For the reasons described in the section entitled “Amendment to the Company’s Certificate of Incorporation (Proposal 1)—Purposes of the Charter Amendment” below, the Board has determined that the Meeting Proposals are fair to and in the best interests of the Company, and in connection therewith, has unanimously approved each of the Meeting Proposals, and unanimously recommends that the Company’s stockholders vote “FOR” each of the Meeting Proposals.

What will happen if the Company’s stockholders do not approve the Charter Amendment Proposal?

If the Charter Amendment Proposal is not approved, we will not have a sufficient number of authorized and unissued shares of common stock to complete the second closing of the Private Placement and our ability to issue additional shares of common stock necessary to finance certain strategic transactions and for general corporate purposes will be significantly limited.

2


How many votes am I entitled to per share?

Each holder of our common stock as of the Record Date is entitled to one vote per share on all matters to be acted upon at the AnnualSpecial Meeting. Each holder of our Series A Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of our common stock into which the Series A Convertible Preferred Stock owned by such holder are convertible as of the Record Date on all matters to be acted upon at the AnnualSpecial Meeting, voting together with the holders of our common stock as a single class. Neither our Certificate of Incorporation nor our Second Amended and Restated Bylaws, as amended (the “Bylaws”), allows for cumulative voting rights. Each proposal is tabulated separately.

How many votes are needed to hold the Special Meeting?

The holders of a majority of the outstanding shares entitled to vote, present in person or represented by proxy, is necessary to constitute a quorum at the AnnualSpecial Meeting. If a quorum is not present or represented at the AnnualSpecial Meeting, a majority of the stockholders entitled to vote at the AnnualSpecial Meeting, present in person or represented by proxy, may adjourn the AnnualSpecial Meeting, from time to time, without notice or other announcement at the AnnualSpecial Meeting until a quorum is present or represented.

PursuantWhat vote is required to our Bylaws, assumingapprove each of the presence ofMeeting Proposals?

If a quorum is present, the approval of the Charter Amendment Proposal requires an affirmative vote of the holders of a majority of the outstanding shares as of the Record Date entitled to vote and the Adjournment Proposal requires the affirmative vote of a majority of the shares as of the Record Date present, in person or represented by proxy, and entitled to vote.

How do I vote?

Voting in Person at the AnnualSpecial Meeting is required. If you are a stockholder of record, you may vote in person at the Special Meeting. If your shares are held in street name and you wish to (i) ratifyvote in person at the appointmentSpecial Meeting, you will need to obtain a “legal proxy” from the broker, bank or other nominee that holds your shares of record.

Voting by Proxy for Shares Registered Directly in the Name of the independent auditors;Stockholder. If you hold your shares in your own name as a holder of record with our transfer agent, Computershare Shareowner Services LLC, you may instruct the proxy holders named in the proxy card how to vote your shares by marking, signing and (ii) approve,dating your proxy card and returning it promptly in the postage-paid envelope provided.

Voting by Proxy for Shares Registered in Street Name. If your shares are held in street name, you will receive instructions from your broker, bank or other nominee that you must follow in order to have your shares voted.

Regardless of how you choose to vote, your vote is important to us and we encourage you to vote promptly.

How can I receive electronic access to the proxy materials?

This Proxy Statement and the accompanying Notice of Special Meeting of Stockholders are available free of charge at www.proxydocs.com/snda and the Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov.

What happens if I return my proxy card without voting on an advisory basis,all proposals?

When you return a properly executed proxy card, the Company’s executive compensation. Company will vote the shares that the proxy card represents in accordance with your directions. If you return the signed proxy card with no direction on a proposal, the Company will vote your proxy “FOR” each of the Meeting Proposals.

What are “broker non-votes” and how are they treated?

Abstentions and “broker non-votes” (as described below), if any, will not be counted as votes cast “FOR” such proposals,any proposal, but may be treated as votes “AGAINST” such proposals. With respect to an uncontested election of directors, assuming the presence of a quorum, each director nominee will be elected to the Board if the number of shares voted “FOR” the election of such director nominee exceeds the number of shares voted “WITHHOLD” for such director nominee (with abstentions and broker non-votes not counted as votes cast either “FOR” or “WITHHOLD” for such director nominee’s election).proposal.

The Board of Directors unanimously recommends that you vote (1) “FOR” the election of each director nominee named in this Proxy Statement, (2) “FOR” the ratification of the appointment of RSM US LLP as our independent auditors for the fiscal year ending December 31, 2022, and (3) “FOR” the approval, on an advisory basis, of the Company’s executive compensation. The Board of Directors also recommends that you vote “FOR” the ability of the proxy holders to vote the proxy in their discretion with respect to any other matters that properly come before the Annual Meeting.

If you hold shares registered directly in your name and you sign and return a proxy card without giving specific voting instructions, the persons named as proxy holders will vote your proxy (1) in favor of the election of each director nominee named in this Proxy Statement, (2) in favor of the ratification of the appointment of RSM US LLP as our independent auditors for the fiscal year ending December 31, 2022, (3) in favor of the approval, on an advisory basis, of the Company’s executive compensation, and (4) as the proxy holders may determine in their discretion with respect to any other matters that properly come before the Annual Meeting.3


If you hold shares in “street name” and do not submit specific voting instructions to your broker, bank or other nominee, the organization that holds your shares may generally vote your shares with respect to “discretionary”“discretionary items, but not with respect to “non-discretionary” items. Discretionary items are proposals considered to be routine under the rules of the NYSE, and in the absence of voting instructions, your broker, bank or other nominee may vote the shares it holds in street name on such items.New York Stock Exchange (the “NYSE”). On non-discretionary items for which you do not submit specific voting instructions to your broker, bank, or other nominee, the shares will be treated as “broker non-votes.” Broker non-votes will be considered present at the AnnualSpecial Meeting for purposes of determining a quorum at the Annual Meeting. The proposal to ratify the appointment of RSM US LLP as our independent auditors for the fiscal year ending December 31, 2022 (Proposal 2) is considered to be routine, and therefore, may be voted upon by your broker, bank or other nominee if you do not provide instructions to such broker, bank or other nominee. However,Special Meeting; however, pursuant to the NYSE’sNYSE rules, brokers, banks or other nominees will not have discretion to vote your shares on the electionproposal to amend our Certificate of directorsIncorporation (Proposal 1) and the advisory vote on

executive compensation (Proposal 3), as such proposals areproposal is considered to be a “non-routine” items.item. An abstention would have the effect of a vote against each of the Meeting Proposals. Broker non-votes will have the effect of a vote against the Charter Amendment Proposal and will have no effect on the outcome of the Adjournment Proposal. We encourage you to provide voting instructions to your broker, bank or other nominee if you hold your shares in street name so that your voice is heard on such matters.

RequestsWho is soliciting the proxy and who pays the costs?

The enclosed proxy for Written Copiesthe Special Meeting is being solicited by the Board. The cost of Annual Reportpreparing, printing, assembling and mailing this Proxy Statement, the accompanying Notice of Special Meeting of Stockholders and the enclosed form of proxy, as well as the reasonable cost of forwarding solicitation materials to the beneficial owners of shares of our stock, and other costs of solicitation, will be exclusively borne by us.

In addition to the solicitation of proxies by mail, our officers, directors and employees may solicit proxies by telephone, telecopy, email or through personal contact. Such officers, directors and employees will not be additionally compensated by us but will be reimbursed for any out-of-pocket expenses. We have retained Georgeson Communications Inc. (“Georgeson”) to assist in the solicitation of proxies for a fee of $8,500 plus expenses and out-of-pocket costs. This amount includes fees payable to Georgeson, but excludes salaries and expenses of our officers, directors and employees. Brokerage houses and other custodians, nominees and fiduciaries will, in connection with shares of our stock registered in their names, be requested to forward solicitation material to the beneficial owners of such shares of our stock.

What happens if the Special Meeting is postponed or adjourned?

If the Special Meeting is postponed or adjourned due to a lack of a quorum or to solicit additional proxies, we intend to reconvene the Special Meeting as soon as reasonably practical, and in any event within 60 days of the Record Date. Pursuant to our Second Amended and Restated Bylaws, as amended (our “Bylaws”), stockholder meetings must be held no more than 60 days following the record date. Your proxy will still be effective and may be voted at the rescheduled or adjourned meeting, and you will still be able to change or revoke your proxy until it is voted at the rescheduled or adjourned meeting, if such meeting occurs within 60 days of the Record Date.

Who should I call if I have questions or need assistance voting my shares?

Please call Georgeson, at (888) 275-0993, if you have any questions or require assistance in connection with voting your shares.

Can I change my vote after I have voted?

Any stockholder giving a proxy has the unconditional right to revoke his or her proxy at any time prior to the voting thereof by attending the Special Meeting and voting in person at the Special Meeting, by delivering a duly executed proxy bearing a later date or by giving written notice of revocation to us addressed to David R. Brickman, Senior Vice President, General Counsel and Secretary, 14755 Preston Road, Suite 810, Dallas, Texas 75254. However, no such revocation will be effective unless such notice of revocation has been received by us at or prior to the Special Meeting.

4


What is “householding” of proxy materials?

This Proxy Statement and accompanying form of proxy are being mailed on or about February [●], 2024. Some banks, brokers and other record holders have begun the practice of “householding” proxy statements and annual reports. “Householding” is the term used to describe the practice of delivering a single copy of this Proxy Statement to any household at which two or more stockholders share an address. This procedure would reduce the volume of duplicative information and our printing and mailing costs. We will provide, without charge,deliver promptly, upon written or oral request, a separate copy of our Annual Report uponthis Proxy Statement to any stockholder at a shared address to which a single copy of such documents was delivered. Any stockholder who would like to receive a separate copy of this Proxy Statement, now or in the writtenfuture, should submit this request of any registered or beneficial owner of our capital stock entitled to vote at the Annual Meeting. Requests should be made by mailing David R. Brickman, Senior Vice President, General Counsel and Secretary, at our principal executive offices, 16301 Quorum Drive,14755 Preston Road, Suite 160A, Addison,810, Dallas, Texas 7500175254, or by calling (972) 770-5600. The SEC also maintains a website at www.sec.govwhich contains reports, proxy statements and other information regarding registrants, including us.

Forward-Looking Statements

Certain information contained inBeneficial owners sharing an address who receive multiple copies of this Proxy Statement constitutes “Forward-Looking Statements” withinand who would like to receive a single copy of such proxy materials in the meaningfuture will need to contact their broker, bank or other nominee to request that only a single copy of Section 27Aeach document be mailed to all stockholders at the shared address in the future.

5


AMENDMENT TO THE COMPANY’S CERTIFICATE OF INCORPORATION

(PROPOSAL 1)

Description of the Securities ActCharter Amendment

Our Certificate of 1933, as amended,Incorporation currently allows us to issue up to 15,000,000 shares of common stock, par value $0.01 per share, and Section 21E15,000,000 shares of preferred stock, par value $0.01 per share. On December 12, 2023, our Board adopted resolutions approving, subject to stockholder approval at the Special Meeting, an amendment to our Certificate of Incorporation to increase the authorized number of shares of common stock to 30,000,000. The Board determined that the Charter Amendment is advisable and in the best interests of the Securities Exchange Act of 1934, as amended, which canCompany and directed that the proposed Charter Amendment be identifiedsubmitted for approval by the useCompany’s stockholders at the Special Meeting. The Charter Amendment does not affect the authorized number of forward-looking terminology such as “may,” “will,” “would,” “intend,” “could,” “believe,” “expect,” “anticipate,” “estimate” or “continue” or the negative thereof or other variations thereon or comparable terminology. Examplesshares of forward-looking statements, include, without limitation, those relatingpreferred stock. The proposed Certificate of Amendment to the Company’sCertificate of Incorporation (the “Certificate of Amendment”) reflecting the foregoing Charter Amendment is attached as Annex A to this Proxy Statement, and this discussion is qualified in its entirety by reference to Annex A.

If the Charter Amendment is approved by our stockholders, it will become effective immediately upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware, which we expect to file promptly after the Special Meeting.

Purposes of the Charter Amendment

Our Certificate of Incorporation currently authorizes the issuance of 15,000,000 shares of common stock, par value $0.01 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share. As of the Record Date, there were (i) [11,528,724] shares of common stock outstanding, (ii) 41,250 shares of Series A Convertible Preferred Stock outstanding, which are convertible into an additional [1,229,311] shares of common stock, (iii) 1,031,250 additional shares of common stock issuable upon the exercise of outstanding warrants, (iv) 350,000 additional shares of common stock issuable pursuant to our equity commitment agreement with affiliates of Conversant, (v) 601,617 additional shares of common stock available for issuance pursuant to our 2019 Plan, and (vi) 23,370 additional shares of common stock issuable upon exercise of outstanding stock options or settlement of RSUs. As a result, as of the Record Date the total number of shares of our common stock issuable on a fully diluted basis and after giving effect to the shares reserved for issuance under the 2019 Plan is approximately [14,764,272] shares, resulting in [235,728] shares available for future business prospectsissuances.

As previously announced, on February 1, 2024 we entered into the Securities Purchase Agreement with the Purchasers, pursuant to which the Purchasers agreed to purchase from us, and strategies, financial results, working capital, liquidity, capital needswe agreed to sell to the Purchasers, in the Private Placement, an aggregate of 5,026,318 Shares of our common stock at a price of $9.50 per share. The Private Placement will occur in two closings. At the first closing, which was completed on February 1, 2024, we issued and expenditures, interest costs, insurance availabilitysold an aggregate of 3,350,878 Shares to the Purchasers and contingent liabilities. Forward-looking statementsreceived gross cash proceeds of $31,833,341. At the second closing, which is anticipated to occur on or around March 31, 2024, we will issue the remaining 1,675,440 Shares to the Purchasers and receive additional gross cash proceeds of $15,916,680. As indicated above, after giving effect to the shares of our common stock that are outstanding and reserved for issuance, we currently do not have a sufficient number of shares of authorized and unissued common stock to complete the second closing of the Private Placement. Accordingly, the second closing is subject to certain risksour stockholders approving the Charter Amendment Proposal (in addition to other customary closing conditions) and uncertaintiesSecurities Purchase Agreement provides that could causewe will use our reasonable best efforts to obtain stockholder approval of the Charter Amendment Proposal at a meeting of the Company’s actual resultsstockholders no later than April 30, 2024. Each Purchaser has also agreed to vote all voting securities of the Company owned or controlled by such Purchaser in favor of the Charter Amendment Proposal. We are seeking approval of the Charter Amendment Proposal at this time to satisfy our obligations under the Securities Purchase Agreement, consummate the second closing of the Private Placement and financial conditionprovide us with flexibility to differ materially from those indicatedissue additional shares of common stock in the forward-looking statements, including, but not limited to:future.

6


Pursuant to the impactSecurities Purchase Agreement, we used approximately $15.4 million of COVID-19, including the actions taken to prevent or contain the spread of COVID-19; the Company’s ability to generate sufficient cash flows from operations, additional proceeds from debt refinancings, andnet proceeds from the sale of assets;the Shares at the first closing to fund the cash portion of the purchase price for the purchase of the outstanding indebtedness of Protective Life Insurance Company that was secured by seven of our senior living communities. We will use the remaining proceeds from the sale of the Shares at the first closing and the proceeds from the sale of the Shares at the second closing, if any, for capital expenditure projects at our senior living communities, working capital, potential acquisition opportunities and other general corporate purposes.

If approved, our Board will have the discretion to issue shares of common stock without further stockholder action, except as may be required for a particular transaction by applicable law or regulation or the NYSE. As of the date hereof, we have no specific agreements or commitments to issue any shares of common stock for which approval of the proposed Charter Amendment is required, except as described herein and pursuant to our 2019 Plan.

Possible Effects of the Charter Amendment

Other than the replacement of the first sentence in the Fourth Article with the proposed sentence set forth in the Charter Amendment, the remaining provisions of the Certificate of Incorporation will be unchanged after effectiveness of the Charter Amendment. If the Charter Amendment is not approved by our stockholders, our Certificate of Incorporation will remain unchanged. In accordance with the Delaware General Corporation Law (the “DGCL”), the Board may elect to abandon the Charter Amendment without further action by the stockholders at any time prior to the effectiveness of the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware, notwithstanding stockholder approval of the Charter Amendment.

The increase in the number of authorized shares of common stock, and the corresponding increase in the total number of shares authorized, will not have an immediate effect on the rights of existing stockholders, nor will it alter the current number of issued shares, except with respect to the additional Shares issuable upon the second closing of the Private Placement (subject to the satisfaction or waiver of the other closing conditions with respect thereto). The issuance of additional shares of common stock at the second closing of the Private Placement or in connection with a future transaction may, among other things, have a dilutive effect on earnings per share and on stockholders’ equity and voting rights. Furthermore, future sales of substantial amounts of our common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of our common stock or limit our ability to raise additional capital. However, in connection with any future transaction, the Board would assess the merits of the transaction and consider, among other things, its potential dilutive effect. The Company will also be required to comply with applicable NYSE rules that require stockholder approval to be obtained in connection with certain dilutive issuances.

The increase in the authorized number of shares of common stock could have possible anti-takeover effects. These authorized but unissued shares could (within the limits imposed by applicable law and NYSE rules) be issued in one or more transactions that could make a change of control of the Company more difficult, and therefore more unlikely. The additional authorized shares could be used to discourage persons from attempting to gain control of the Company by diluting the voting power of shares then outstanding or increasing the voting power of persons who would support the Board in a potential takeover situation, including by preventing or delaying a proposed business combination that is opposed by the Board although perceived to be desirable by some stockholders.

Neither the DGCL, nor our Certificate of Incorporation or Bylaws, provide for approval or other similar rights for dissenting shareholders in connection with this proposal or the Adjournment Proposal. Accordingly, our stockholders will have no right to dissent and obtain payment for their shares.

For the reasons stated above, the Board determined that the Charter Amendment is advisable and in the best interest of our Company and its stockholders and authorized and approved the Charter Amendment Proposal and directed that it be considered by the Company’s ability to obtain additional capital on terms acceptable to it;stockholders at the Company’s ability to extend or refinance its existing debt as such debt matures; the Company’s compliance with its debt agreements, including certain financial covenants, and the riskSpecial Meeting.

7


Required Vote for Stockholder Approval

The affirmative vote of cross-default in the event such non-compliance occurs; the Company’s ability to complete acquisitions and dispositions upon favorable terms or at all; the risk of oversupply and increased competition in the markets which the Company operates; the risks related to an epidemic, pandemic or other health crisis, such as the COVID-19 pandemic, including the transmission of its highly contagious variants and sub-lineages, and the development and availability of vaccinations and other related treatments; the risk of increased competition for skilled workers due to wage pressure and changes in regulatory requirements; the departurea majority of the Company’s key officers and personnel; the cost and difficulty of complying with applicable licensure, legislative oversight, or regulatory changes; the risks associated with a decline in economic conditions generally; the adequacy and continued availabilityoutstanding shares as of the Company’s insurance policiesRecord Date entitled to vote is required to approve this proposal. Abstentions and “broker non-votes,” if any, will not be counted as votes cast “FOR” such proposal, but may be treated as votes “AGAINST” such proposal.

Recommendation of the Company’s ability to recover any losses it sustains under such policies; changes in accounting principlesBoard of Directors

The Board unanimously recommends a vote “FOR” the approval and interpretations; andadoption of the other risks and factors identified from time to time in the Company’s reports filed with the SEC.Charter Amendment.

8


ADJOURNMENT PROPOSAL

(PROPOSAL 2)

The Board is recommending that stockholders approve, if necessary, adjournment of the Special Meeting to solicit additional proxies in favor of the Charter Amendment Proposal if there are insufficient proxies at the Special Meeting to approve the Charter Amendment Proposal. Any adjournment of the Special Meeting for the purpose of soliciting additional proxies will allow stockholders who have already sent in their proxies to revoke them at any time prior to the time that the proxies are used.

The Board unanimously recommends a vote “FOR” the approval of the Adjournment Proposal.

9


PRINCIPAL STOCKHOLDERS AND STOCK OWNERSHIP OF MANAGEMENT

The following table sets forth certain information with respect to the beneficial ownership of our capital stock as of April 18, 2022February 12, 2024 by: (i) each person known by us to be the beneficial owner of more than five percent of our capital stock; (ii) each of our directors and director nominees;directors; (iii) each of our “named executive officers” set forth in the Summary Compensation Table below;; and (iv) all of our current executive officers and directors as a group. Except as otherwise indicated, the address of each person listed below is 16301 Quorum Drive,14755 Preston Road, Suite 160A, Addison,810, Dallas, Texas 75001.75254.

 

   Shares Beneficially Owned(1) 

Name of Beneficial Owner

  Number   Percent of Class 

5% or More Stockholder

    

Conversant Capital LLC(2)

   5,047,981    57.2

Seymour Pluchenik(3)

   855,748    9.7

Arbiter Partners Capital Management LLC(4)

   613,820    7.0

Peter DeSorcy (5)

   582,378    6.6

Named Executive Officers and Directors

    

Kimberly S. Lody(6)

   170,272    1.9

Brandon M. Ribar(7)

   85,414    * 

David R. Brickman(8)

   61,904    * 

Philip A. Brooks(9)

   7,227    * 

Jill M. Krueger(10)

   7,134    * 

Noah R. Beren(11)

   863     

Benjamin P. Harris(12)

   3,074     

David W. Johnson

   0     

Max J. Levy

   0     

Shmuel S.Z. Lieberman

   0     

Elliot R. Zibel

   0     

All directors and executive officers as a group (14 persons)(13)

   443,108    5.0
   Shares Beneficially Owned(1) 

Name of Beneficial Owner

  Number   Percent of Class 

5% or More Stockholder

    

Conversant Capital LLC(2)

   9,821,437    62.0

Seymour Pluchenik(3)

   2,449,593    15.5

Named Executive Officers and Directors

    

Brandon M. Ribar(4)

   228,727    1.4

Kevin J. Detz(5)

   138,154    * 

David R. Brickman(6)

   93,342    * 

Jill M. Krueger(7)

   13,047    * 

Noah R. Beren(8)

   10,276    * 

Benjamin P. Harris(9)

   8,987    * 

Shmuel S.Z. Lieberman(10)

   6,913    * 

David W. Johnson(11)

   5,913    * 

Elliot R. Zibel(12)

   5,913    * 

Max J. Levy

        

Kimberly S. Lody(13)

       * 

All directors and executive officers as a group (14 persons)(14)

   677,213    4.3

 

*

Less than one percent.

 

(1)

The percentages indicated are based on the sum of (i) 6,755,938[11,528,724] shares of our common stock issued and outstanding on April 18, 2022, February 12, 2024, plus (ii) 9,816 shares of common stock underlying the vested portion of an option to purchase shares of common stock, plus (iii) 1,031,2501,229,311 shares of our common stock issuable in the aggregate upon conversion of the Series A Convertible Preferred Stock held by Conversant Dallas Parkway (A) LP (“Conversant Fund A”) and Conversant Dallas Parkway (B) LP (“Conversant Fund B” and, together with Conversant Fund A, the “Conversant Investors”), plus (iv) 1,031,250 shares of our common stock issuable in the aggregate upon exercise of the Company’s warrants held by the Conversant Investors.Investors, plus (v) 350,000 shares of our common stock issuable upon draws by the Company under the Conversant Equity Commitment, plus (vi) 13,554 shares of our common stock underlying restricted stock units held by non-employee directors, plus (vii) 1,675,440 shares of our common stock issuable upon the second closing of the Private Placement.

 

(2)

The address of the reporting persons reported on this line is c/o Conversant Capital LLC, 25 Deforest Avenue, Summit, NJ 07901. Conversant Capital LLC (“Conversant Capital”) is the investment manager of and makes investment decisions for the Conversant Investors. Conversant GP Holdings LLC (“Conversant GP”) is the general partner of each of the Conversant Investors. Michael J. Simanovsky is the managing member of Conversant GP. By virtue of these relationships, each of Conversant Capital, Conversant GP, and Mr. Simanovsky may be deemed to beneficially own shares (including shares of common stock issuable upon conversion of Series A Convertible Preferred Stock or upon exercise of warrants to purchase common stock) owned directly by the Conversant Investors. Shares reported on this line consist of 2,985,481(i) 6,158,244 shares of issued and outstanding common stock; 1,031,250stock, (ii) 1,229,311 shares of common stock issuable upon conversion of 41,250 shares of the Company’s Series A Convertible Preferred Stock, which constitutes 100% of the issued and outstanding shares of Series A Convertible Preferred Stock as of April 15, 2022; andDecember 31, 2023, (iii) 1,031,250 shares of common stock issuable upon exercise of warrants, (iv) 350,000 shares of

10


common stock issuable upon draws by the Company under the Conversant Equity Commitment, and (v) 1,052,632 shares issuable upon the second closing of the Company,Private Placement, in each case, held in the aggregate by the Conversant Investors. Conversant Fund A has sole voting power and dispositive power with respect to

none of the shares and shared voting power and dispositive power with respect to 4,741,016 shares.7,909,565 shares and Conversant Fund B has sole voting power and dispositive power with respect to none of the shares and shared voting power and dispositive power with respect to 306,965 shares.1,713,811 shares, plus, in each case the additional shares of common stock issuable in respect of accrued and unpaid dividends on the shares of Series A Convertible Preferred Stock held by Conversant Fund A and Conversant Fund B. Each of Conversant GP, Mr. Simanovsky and Conversant Capital has sole voting power and dispositive power with respect to none of the shares and shared voting power and dispositive power with respect to 5,047,9819,821,437 shares. The foregoing information regarding Conversant Capital, the Conversant Investors, Conversant GP, Mr. Simanovsky, and their respective beneficial ownership of shares is based solely on a Schedule 13D13D/A filed on November 12, 2021.16, 2023 after giving effect to the Private Placement.

 

(3)

The address of the reporting persons reported on this line is c/o GF Investments, 810 Seventh Avenue, 28th Floor, New York, NY 10019. Shares reported on this line represent shares that may be deemed to be beneficially owned by Seymour Pluchenik, Sam Levinson, Simon Glick, Silk Partners, LP (“Silk”); Siget, LLC (“Siget”); Siget NY Partners, L.P. (“Siget NY”); 1271 Associates, LLC (“1271 Associates”); and PF Investors, LLC (“PF Investors”). Mr. Levinson is the chief investment officer of Siget NY. Siget NY is the investment manager of and makes investment decisions for Silk. 1271 Associates is the General Partner of Siget NY. Messrs. Glick and Pluchenik are the managing members of 1271 Associates. Siget is the General Partner of Silk. Messrs. Glick and Pluchenik are the managing members of Siget. By virtue of these relationships, each of Siget NY, 1271 Associates, Siget and Messrs. Levinson, Glick and Pluchenik may be deemed to beneficially own the shares owned directly by Silk. Mr. Pluchenik is the manager of PF Investors, and by virtue of this relationship, Mr. Pluchenik may be deemed to beneficially own the shares owned directly by PF Investors. Based solely on a Schedule 13D/A filed on December 10, 2021February 5, 2024, and subsequent Form 4 filings on December 21, 2021 and January 10, 2022,after giving effect to the Private Placement, (i) Seymour Pluchenik has the sole voting and dispositive power with respect to none of the shares and shared voting and dispositive power with respect to 855,7482,449,593 shares, (ii) Sam Levinson, Simon Glick, Siget, Siget NY and 1271 Associates have the sole voting and dispositive power with respect to none of the shares and shared voting and dispositive power with respect to 792,6902,234,754 shares, (iii) Silk has sole voting and dispositive power with respect to 792,6902,234,754 shares that are held by Silk directly and shared voting and dispositive power with respect to none of the shares, and (iv) PF Investors has the sole voting and dispositive power with respect to 63,058214,839 shares that are held directly by PF Investors and shared voting and dispositive power with respect to none of the shares. The shares reported in this line include 1,052,632 shares issued to Silk and PF Investors, collectively, upon the first closing of the Private Placement and 526,316 shares issuable to Silk and PF Investors, collectively, upon the second closing of the Private Placement.

 

(4)

The address of Arbiter Partners Capital Management LLC (“Arbiter Partners”) is 530 Fifth Avenue, 20th Floor, New York, NY 10036. Arbiter Partners and Paul J. Isaac share voting power and share dispositive power with respect to 604,876 of the reported shares, and Paul J. Isaac has sole voting power and dispositive power with respect to 8,944 of the reported shares. Information relating to Arbiter Partners is based on a Schedule 13D filed with the SEC on March 10, 2017 and a Schedule 13D/A filed with the SEC on November 12, 2021. Arbiter Partners is a registered investment adviser that manages and/or administers Arbiter Partners QP LP, an affiliated investment fund (“APQ”), and various accounts, including Isaac Brothers, LLC, Nana Associates LLC and 9 Interlaken Partners LLC (collectively, the “Family Accounts”). Mr. Isaac controls Arbiter Partners. By reason of its position as investment adviser to APQ and as manager and/or administrator of the Family Accounts, Arbiter Partners may be deemed to possess the power to vote and dispose of theIncludes shares held by APQMr. Ribar directly and the Family Accounts. By reason of his responsibility for the supervision and conduct of all investment activities of Arbiter Partners, Mr. Isaac may be deemed to possess the power to vote and dispose of the shares beneficially owned by Arbiter Partners. Mr. Isaac disclaims beneficial ownership of these securities for all purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein.

(5)

The address of the reporting persons reported on this line is 450 Park Avenue, Suite 2700, New York, NY 10022. Shares reported on this line represent shares that may be deemed to be beneficially owned by Pangea Ventures, L.P. (“Pangea”), Ortelius Advisors, L.P. (“Ortelius Advisors”), Ortelius Capital Partners, LLC (“Ortelius Capital”), Hudson Investors, Ltd. (“Hudson”) and Peter DeSorcy. Ortelius Advisors is the investment manager of Pangea and Ortelius Capital is the investment manager of Hudson. Mr. DeSorcy is

the Managing Member of the general partner of Ortelius Advisors, is a Managing Member of Ortelius Advisors and has a controlling interest in Ortelius Advisors, and, as a result, Mr. DeSorcy may be deemed to beneficially own the shares beneficially owned by Pangea. Mr. DeSorcy also co-owns Ortelius Capital and is a Managing Member of Ortelius Capital with dispositive and voting control over portfolios managed by Ortelius Capital, and, as a result Mr. DeSorcy may be deemed to beneficially own the shares beneficially owned by Hudson. Each of Pangea, Ortelius Advisors, Ortelius Capital, Hudson and Peter DeSorcy has sole voting and dispositive power with respect to none of the shares. Panega and Ortelius Advisors have shared voting and dispositive power with respect to 459,378 shares, Hudson and Ortelius Capital have shared voting and dispositive power with respect to 123,000 shares, and Mr. DeSorcy has shared voting and dispositive power with respect to 582,478 shares. The foregoing information regarding Pangea, Ortelius Advisors, Ortelius Capital, Hudson and Peter DeSorcy and their respective beneficial ownership of shares is based solely on a Schedule 13D/A filed on November 30, 2021.

(6)

Consists of 25,373 shares held by Ms. Lody directly, 135,083 unvested shares of restricted stock (78,015(certain of which are subject to the Company’s achievement of certain performance targets), and 9,816 shares of common stock underlyingas disclosed in the vested portion of an option to purchase shares of common stock at $111.90 per share.Company’s Form 4 filings with the SEC.

 

(7)(5)

Consists of 12,266Includes shares held by Mr. RibarDetz directly and 73,148 unvested shares of restricted stock (49,374(certain of which are subject to the Company’s achievement of certain performance targets)., as disclosed in the Company’s Form 4 filings with the SEC.

 

(8)(6)

Consists of 14,460Includes shares held by Mr. Brickman directly and 47,444 unvested shares of restricted stock (31,733(certain of which are subject to the Company’s achievement of certain performance targets)., as disclosed in the Company’s Form 4 filings with the SEC.

(7)

Consists of 8,233 shares held by Ms. Krueger directly, 3,000 unvested shares of restricted stock and 1,814 shares of common stock underlying vested restricted stock units.

11


(8)

Consists of 4,363 shares held by Mr. Beren directly, 3,000 unvested shares of restricted stock and 2,913 shares of common stock underlying vested restricted stock units.

 

(9)

Consists of 5,3873,074 shares held by Mr. BrooksHarris directly, 418 shares held by the Brooks Joint Revocable Trust, and 1,4223,000 unvested shares of restricted stock.stock and 2,913 shares of common stock underlying vested restricted stock units.

 

(10)

Consists of 5,7123,913 shares held by Ms. KruegerMr. Lieberman directly and 1,422 unvested3,000 shares of unvested restricted stock.

 

(11)

Consists of 8633,000 shares held by Mr. Beren directly.of unvested restricted stock and 2,913 shares of common stock underlying vested restricted stock units.

 

(12)

Consists of 3,0742,913 shares held by Mr. Harris directly.Zibel directly and 3,000 shares of common stock underlying unvested restricted stock units.

 

(13)

Includes 75,193Ms. Lody resigned as the Company’s President and Chief Executive Officer, effective September 2, 2022, and the Company has been unable to determine the number of shares of its common stock held by Ms. Lody, if any.

(14)

Consists of shares held directly or indirectly by the executive officers and directors of the Company 358,099and unvested shares of restricted stock (234,374(certain of which are subject to the Company’s achievement of certain performance targets) and 9,816, as disclosed in the Company’s Form 4 filings with the SEC, as well as 13,554 shares of common stock underlying the vested portion of an option to purchase shares of commonrestricted stock at $111.90 per share.units held by non-employee directors.

Forward-Looking Statements

ELECTION OF DIRECTORS

(PROPOSAL 1)

NomineesCertain information contained in this Proxy Statement constitutes “Forward-Looking Statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Continuing Directors

Unless otherwise directedSection 21E of the Securities Exchange Act of 1934, as amended, which can be identified by the use of forward-looking terminology such as “may,” “will,” “would,” “intend,” “could,” “believe,” “expect,” “anticipate,” “estimate” or “continue” or the negative thereof or other variations thereon or comparable terminology. Examples of forward-looking statements, include, without limitation, those relating to timing and completion of the second closing of the Private Placement. Forward-looking statements are subject to certain risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially from those indicated in the proxy, it isforward-looking statements, including, but not limited to, our ability to obtain the intentionstockholder approval of the persons named in such proxyCharter Amendment Proposal; the satisfaction of all conditions to vote the shares represented by such proxy for the election of eachsecond closing of the following nominees as a memberPrivate Placement; other risks related to the consummation of the Private Placement, including the risk that the second closing of the Private Placement will not be consummated within the expected time period or at all; the costs related to the Private Placement; the impact of the Private Placement on the Company’s business; any legal proceedings that may be brought related to the Private Placement; and the other risks and factors identified from time to time in the Company’s reports filed with the SEC.

12


OTHER MATTERS

Our Bylaws provide that only business within the purpose or purposes described in the notice of special meeting may be conducted at such special meeting. Accordingly, no business other than the identified proposals shall be conducted at the Special Meeting.

STOCKHOLDER PROPOSALS FOR THE 2024 ANNUAL MEETING

Our Certificate of Incorporation establishes an advance notice procedure with regard to certain matters, including stockholder proposals and nominations of individuals for election to the Board, to be proposed at an annual meeting of Directors, eachour stockholders. Notice of a stockholder proposal or a director nomination to hold office until thebe brought at an annual meeting of our stockholders tomust be held in 2025 and until his successor is duly qualified and elected or until his earlier resignation or removal. Messrs. Brooks, Harris and Johnson are presently members of the Board of Directors.

Our Board is divided into three classes: Class I (terms expire at 2022 annual meeting), Class II (terms expire at 2023 annual meeting) and Class III (terms expire at 2024 annual meeting). The Board currently consists of nine directors with three directors in each of Class.

As further discussed below under “Board of Directors and Committees—Investor Rights Agreement,” on November 3, 2021 we entered into an agreement (the “Investor Rights Agreement”) with Conversant Dallas Parkway (A) LP (“Conversant Fund A”), Conversant Dallas Parkway (B) LP, affiliates of Conversant Capital LLC (“Conversant Fund B” and, together with Conversant Fund A, the “Conversant Investors”), and Silk Partners, LP (“Silk”) pertaining to, among other things, the appointment of a certain number of designees of Conversant Fund A and Silk, respectively, to the Board. Pursuant to the terms of the Investor Rights Agreement, Conversant Fund A is entitled to designate four individuals to be appointed to the Board and the Chairman of the Board and Silk is entitled to designate two individuals to be appointed to the Board. Conversant Fund A designated Benjamin P. Harris, David W. Johnson, Max J. Levy, and Elliot R. Zibel as its director designees with Mr. Johnson as Chairman of the Board and Silk designated Noah R. Beren and Shmuel S.Z. Lieberman as its director designees, and such individuals were appointed to the Board in November 2021.

Name

  Age   

Position(s)

  Class   Director’s
Term Expires
 

Nominees:

        

Philip A. Brooks

   63   

Director

   I    2022 

Benjamin P. Harris

   47   

Director

   I    2022 

David W. Johnson

   60   

Director

   I    2022 

Continuing Directors:

        

Kimberly S. Lody

   56   

Chief Executive Officer, President and Director

   II    2023 

Noah R. Beren

   41   

Director

   II    2023 

Shmuel S.Z. Lieberman

   37   

Director

   II    2023 

Jill M. Krueger

   62   

Director

   III    2024 

Max J. Levy

   31   

Director

   III    2024 

Elliot R. Zibel

   41   

Director

   III    2024 

The following is a brief biography of each nominee and each director whose term will continue after the Annual Meeting.

Nominees for Election for Three-Year Terms Expiring at the 2025 Annual Meeting:

Philip A. Brooks has been a director since 2010. He is a principal investor and managing partner in Select Living, LLC, which acquires properties to develop to special market dynamics. Mr. Brooks has more than 30 years of experience as a financier and investor, credit manager, and product/policy analyst, and he has been involved in $15 billion of seniors housing debt and equity transactions. Mr. Brooks is the Vice Chair of the Virginia Community Development Corporation, which invests in affordable multifamily and seniors properties throughout Virginia. He is also a portfolio advisor to NRV, a venture capital firm funding early stage growth companies. Mr. Brooks received a B.S. in History and Political Science from the University of Tennessee.

Benjamin P. Harris, CFA, has been a director since November 2021. He is the founder and CEO of Pinedale Capital Partners, a dedicated industrial real estate operating platform based in New York. Previously, Mr. Harris was the CEO of Link Logistics (Blackstone’s U.S. Industrial Real Estate platform). Before that, he served as President of Gramercy Property Trust (NYSE: GPT), the Head of Net Lease Investments of Northcliffe/Annaly Capital Management and the Head of U.S. Investments of W. P. Carey & Co. LLC (NYSE: WPC). Mr. Harris received a Joint BSc in Economics from the University of Kings College/Dalhousie University, Canada.

David W. Johnson has been a director since November 2021. He is Co-Founder & Managing Director of Horizon Capital, a land acquisition and land development company. Prior to Horizon Capital, he founded Aimbridge Hospitality and served as its CEO. Mr. Johnson previously spent 17 years at Wyndham International, where he helped add over 400 hotels to the Wyndham portfolio. Additionally, he served as President of Wyndham Hotels, overseeing approximately 15,000 employees and $3 billion in annual revenue. Mr. Johnson serves as a Director on the Board of Hilton Grand Vacations Inc. (NYSE: HGV) and sits on the Audit and Compensation Committees. Previously, he served on the Strategic Hotels (NYSE: BEE) Board as a member of the Audit and Corporate Governance Committees, and as a Director of Gaylord Entertainment (NYSE: GET). He is also on the U.S. Travel Association (USTA) board as a member of the Chairman’s Circle and as a member of USTA’s CEO Roundtable. Mr. Johnson received a bachelor’s degree in Business Economics from Northeastern Illinois University.

Directors Continuing in Office Until the 2023 Annual Meeting:

Kimberly S. Lody has been a director since 2014. She has been Chief Executive Officer and President of Sonida Senior Living, Inc. since January 2019. Previously, she served as North America President and Senior Vice President of GN Hearing, a global manufacturer of hearing instruments and hearing protection devices. Ms. Lody has more than 26 years of senior management experience in a variety of clinical and commercial health care settings, including health insurance, durable medical equipment, home healthcare, infusion therapy, respiratory therapy, specialty pharmaceuticals and medical devices. In addition, Ms. Lody serves on the Board of Directors of ConvaTec Group Plc (LON: CTEC), a global medical products and technologies company, where she also serves on both the Nomination Committee and Remuneration Committee of the Board. She also serves on the board of Argentum and on the NIC Operator Advisory Board. She received a Master of Business Administration degree from Wake Forest University and a Bachelor of Arts degree in business administration from Hiram College.

Noah R. Beren has been a director since November 2021. He joined GF Investments in 2014 and is currently Head of Asset Management for the firm. His responsibilities include overseeing an extensive real estate portfolio of office, multi-family and land assets. Previously he served as a Vice President focusing on deal execution and portfolio management. From 2012 to 2014, Mr. Beren served as a Vice President at a private independent oil and gas company. Mr. Beren received a First Talmudic Degree from Talmudical Yeshiva of Philadelphia.

Shmuel S.Z. Lieberman has been a director since November 2021. He is a senior member of the investment team at GF Investments. Mr. Lieberman oversees the investment process for public and private investments across a wide range of industries, strategies and asset classes. He is a former board member of TradAir Ltd and has been an observer to a number of portfolio companies. Mr. Lieberman received a Master of Business Administration degree from Baruch College and a Bachelor of Rabbinic Studies degree from the Rabbinical College of America.

Directors Continuing in Office Until the 2024 Annual Meeting:

Jill M. Krueger has been a director since 2004. She is the founding President and Chief Executive Officer of Symbria, Inc., a company that provides integrated ancillary services to nursing and senior living providers that

include therapy, pharmacy and well-being. She also serves on the Board of Directors of iMedia Brands, Inc. (NASDAQ: IMBI), where she is Chairperson of the Audit Committee, and is a member of the Board of Directors of the American Board of Post-Acute and Long-Term Care Medicine and the Board of Directors of the Senior Care Pharmacy Coalition. Before she joined Symbria, Inc., Ms. Krueger was a partner at KPMG LLP responsible for overseeing the firm’s national Long-Term Care and Retirement Housing Practice. She received a B.S. from Northern Illinois University. She is a Certified Public Accountant and a Certified Management Accountant.

Max J. Levy has been a director since November 2021. Mr. Levy is a Principal at Conversant Capital LLC. From 2015-2020, Mr. Levy was an investment analyst at The Baupost Group where he focused on real estate investments in North America and Europe. During this time, Mr. Levy was responsible for sourcing and evaluating equity and debt investments in all property types in both private real estate and public securities. Before joining Baupost, Mr. Levy began his career as an investment banking analyst for Hentschel & Company, a boutique real estate advisory firm, where he assisted public REITs and private real estate companies on mergers, acquisitions, and capital raising. He received a B.A. in Intellectual History from the University of Pennsylvania where he graduated summa cum laude and was elected to Phi Beta Kappa.

Elliot R. Zibel, CFA, has been a director since November 2021. He is the CEO and Co-Founder of Select Dental Management, which he helped found. Mr. Zibel is responsible for M&A, strategy and operations for 32 practice Dental Support Organizations, and has completed 30 acquisitions and raised more than $70 million of equity and debt capital from institutional investors during his tenure. Previously, he worked in the financial sector at multi-billion-dollar firms including Hitchwood Capital Management L.P., Folger Hill Asset Management, Pennant Capital Management, Breeden Partners L.P. and Matrix Asset Advisors LLC. Mr. Zibel received a Bachelor of Economics and Political Science from Union College.

When considering whether directors and nominees have the experience, qualifications, attributes and skills, taken as a whole, to enable the Board to satisfy its oversight responsibilities effectively in light of the Company’s business and structure, the Board and the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) focused primarily on the information discussed in each of the Directors’ individual biographies set forth above. In particular, with respect to Mr. Beren, the Board considered his substantial experience in the real estate industry. With respect to Mr. Brooks, the Board considered his extensive experience in the senior living industry and strong background in senior housing financing. With regard to Mr. Harris, the Board considered his significant experience in real estate investments, development, leasing and operation, including serving as President a publicly-traded REIT. With respect to Mr. Johnson, the Board considered his extensive experience in the hospitality industry, including serving as CEO of a leading hotel management company, along with his prior service as a director for several public companies. With respect to Ms. Krueger, the Board considered her significant experience, expertise and background with regard to accounting matters, which includes specialization in health care, and rehabilitative and wellness services for elderly persons. With respect to Mr. Levy, the Board considered his substantial experience in real estate and investment banking. With respect to Mr. Lieberman, the Board considered his significant investment experience. With respect to Ms. Lody, in addition to her many years of experience with the Company, including most recently as its President and Chief Executive Officer, the Board considered Ms. Lody’s executive level experiences in marketing services and products to seniors as well as successfully managing, growing and branding companies within the healthcare industry. With respect to Mr. Zibel, the Board considered his significant management experience in the healthcare industry, including his experience with a large national service provider to senior living communities. In addition, with respect to Messrs. Levy, Beren and Lieberman, the Board considered that such individuals could bring to the Board an important perspective of significant stockholders of the Company. As noted below under “Board of Directors and Committees—Investor Rights Agreement,” the Company is obligated to nominate Messrs. Beren, Harris, Johnson, Levy, Lieberman and Zibel as directors pursuant to the terms of the Investor Rights Agreement.

The Board does not anticipate that any of the aforementioned nominees for director will refuse or be unable to accept election as a director, or be unable to serve as a director. Should any of them become unavailable for

nomination or election or refuse to be nominated or to accept election as a director, then the persons named in the enclosed form of proxy intend to vote the shares represented in such proxy for the election of such other person or persons as may be nominated or designated by the Board.

There are no family relationships among any of our directors, director nominees or executive officers.

The Board of Directors unanimously recommends a vote “FOR” the election of each of the individuals nominated for election as a director.

BOARD OF DIRECTORS AND COMMITTEES

General

Our Board of Directors currently consists of nine directors and is expected to consist of nine directors following the Annual Meeting. The Board has determined that Noah R. Beren, Phillip A. Brooks, Benjamin P. Harris, David W. Johnson, Jill M. Krueger, Max J. Levy, Shmuel S.Z. Lieberman and Elliot R. Zibel, each an existing director, are “independent” within the meaning of the corporate governance rules of the NYSE and no such individual has any relationship with us, except as a director, stockholder and/or director nominee, as applicable. In addition, we have adopted a Director Independence Policy, as described in greater detail below under the heading “—Director Independence Policy,” which establishes guidelines for the Board to follow in making the determination as to which of our directors is “independent.” Our Director Independence Policy is available on our website at http://www.sonidaseniorliving.com in the Investor Relations section and is available in print to any stockholder who requests it. The Board has determined that Messrs. Beren, Brooks, Harris, Johnson, Levy, Lieberman and Zibel and Ms. Krueger, each an existing director, are “independent” in accordance with our Director Independence Policy.

During 2021, the Board held 13 board meetings, including regularly scheduled and special meetings. During 2021, no incumbent director attended fewer than 75% of the aggregate of (i) the total number of meetings of the Board (held during the period for which he or she has been a director) and (ii) the total number of meetings held by all committees of the Board on which such director served (during the periods that he or she served). Under our Corporate Governance Guidelines, each of our directors is expected to attend all meetings of the Board, the annual stockholders meeting and meetings of the committees of the Board on which they serve. Each of our directors (other than Mr. Zibel) attended our 2021 annual meeting of stockholders. Our independent directors meet in executive sessions without any management directors, and the independent Chairman of the Board presided over these meetings during 2021.

Advance Resignation Policy

Under our Corporate Governance Guidelines, for uncontested director elections, as a condition to nomination by the Board of an incumbent director, such nominee must submit an irrevocable resignation to the Board. Any such nominee who receives a greater number of votes “withholding authority” for or “against” such nominee’s election than votes “for” such nominee’s election (with abstentions and broker non-votes not counted as votes cast either “for” or “withhold authority” for or “against” such nominee’s election), and who remains on the Board as a holdover director, will have his or her irrevocable resignation considered by the Nominating and Corporate Governance Committee. Following the certification of the voting results in an uncontested election of directors, the Nominating and Corporate Governance Committee will make a recommendation to the Board as to the treatment of any such nominee that did not receive the requisite majority vote, including whether to accept or reject any such tendered resignation. Thereafter, the Board will determine whether to accept the Nominating and Corporate Governance Committee’s recommendation. If such nominee’s resignation is accepted by the Board, then such director will immediately cease to be a member of the Board upon the date of such acceptance.

Director Independence Policy

The Board undertakes an annual review of the independence of all non-management directors. In advance of the meeting at which this review occurs, each non-management director is asked to provide the Board with full information regarding the director’s business and other relationships with us in order to enable the Board to evaluate the director’s independence. Directors have an affirmative obligation to inform the Board of any material changes in their circumstances or relationships that may impact their designation by the Board as “independent.” This obligation includes all business relationships between, on the one hand, directors or members of their immediate family, and, on the other hand, us, whether or not such business relationships are described above.

No director qualifies as “independent” unless the Board affirmatively determines that the director has no material relationship with us. The following guidelines are considered in making this determination:

a director who is, or has been within the last three years, employed by us, or whose immediate family member is, or has been within the last three years, one of our executive officers, is not “independent”;

a director who received, or whose immediate family member received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from us, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such compensation is not contingent in any way on continued service), is not “independent”;

a director (a) who is or whose immediate family member is a current partner of a firm that is our internal or external auditor, (b) who is a current employee of such a firm, (c) whose immediately family member is a current employee of such a firm and participates in the firm’s audit, assurance or tax compliance (but not tax planning) practice, or (d) who is, or whose immediate family member was within the last three years (but is no longer), a partner or employee of such a firm and personally worked on our audit within that time, is not “independent”;

a director who is, or whose immediate family member is, or has been within the last three years, employed as an executive officer of another company where any of our present executive officers at the same time serves or served on that other company’s compensation committee, is not “independent”;

a director who is a current employee, or whose immediate family member is a current executive officer, of a company that has made paymentsdelivered to, or received payments from, us for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1 million or 2% of such other company’s consolidated gross revenues, is not “independent”;

a director who serves as an executive officer, or whose immediate family member serves as an executive officer, of a tax exempt organization that, within the preceding three years, received contributions from us, in any single fiscal year, of an amount equal to the greater of $1 million or 2% of such organization’s consolidated gross revenue, is not “independent”; and

a director who has a beneficial ownership interest of 10% or more in a company which has received remuneration from us in any single fiscal year in an amount equal to the greater of $1 million or 2% of such company’s consolidated gross revenue is not “independent” until three years after falling below such threshold.

In addition, members of the Compensation Committee must not have any relationship or affiliation with us that would materially affect the director’s ability to be independent from management as a Compensation Committee membermailed and must otherwise be “independent” under our Director Independence Policy. Members of the Audit Committee may not accept any consulting, advisory or other compensatory fee from us or any of our subsidiaries or affiliates other than directors’ compensation.

The terms “us,” “we” and “our” refer to Sonida Senior Living, Inc. and any direct or indirect subsidiary of Sonida Senior Living, Inc., which is part of the consolidated group. An “immediate family member” includes a person’s spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law and anyone (other than domestic employees) who shares such person’s home.

Committees

Committees of the Board include the Audit Committee, the Nominating and Corporate Governance Committee, and the Compensation Committee.

Audit Committee

The Audit Committee consists of Ms. Krueger (chair) and Messrs. Brooks, Harris and Johnson, each of whom is “independent” as defined by the listing standards of the NYSE in effect as of the date of this Proxy Statement.

The Board has determined that Ms. Krueger qualifies as an “audit committee financial expert” within the meaning of SEC regulations. The Board has adopted an amended and restated Audit Committee Charter, which is available on our website at http://www.sonidaseniorliving.com in the Investor Relations section and is also available in print to any stockholder who requests a copy. Pursuant to its charter, the Audit Committee:

oversees our financial reporting process and internal control system;

appoints, replaces, provides for compensation of and oversees our independent accountants;

provides an open avenue of communication among our independent accountants, senior management and the Board; and

conducts an annual review of the adequacy of its charter and recommends any proposed changes to the Board for its approval.

During 2021, the Audit Committee held five meetings, including regularly scheduled and special meetings.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee consists of Messrs. Brooks (chair), Beren and Zibel and Ms. Krueger, each of whom is “independent” as defined by the listing standards of the NYSE in effect as of the date of this Proxy Statement. The Board has adopted an amended and restated Nominating and Corporate Governance Committee Charter, which is available on our website at http://www.sonidaseniorliving.com in the Investor Relations section and is also available in print to any stockholder who requests a copy. Pursuant to its charter, the Nominating and Corporate Governance Committee:

identifies individuals qualified to become directors;

recommends director nominees to the Board;

develops, and recommends for Board’s approval, our Corporate Governance Guidelines;

reviews with management and assists and advises the Board with respect to resident care and services;

oversees the evaluation of the Board and management; and

conducts an annual review of the adequacy of its charter and recommends any proposed changes to the Board for its approval.

During 2021, the Nominating and Corporate Governance Committee held two meetings, including regularly scheduled and special meetings.

Compensation Committee

Composition, Charter and Meetings

The Compensation Committee consists of Messrs. Lieberman (chair) and Levy and Ms. Krueger, each of whom is “independent” as defined by the listing standards of the NYSE in effect as of the date of this Proxy Statement. The Board has adopted an amended and restated Compensation Committee Charter, which is available on our website at http://www.sonidaseniorliving.com in the Investor Relations section and is also available in print to any stockholder who requests a copy. Pursuant to its charter, the Compensation Committee’s responsibilities include, among other things, the responsibility to:

review and approve, on an annual basis, the corporate goals and objectives, and any amendments to those goals and objectives, relevant to the compensation of our Chief Executive Officer and our other executive officers, evaluate each such individual’s performance in light of such objectives and, either as a committee or together with other independent directors (as directed by the Board), determine and approve the compensation for each such individual based on such evaluation (including base salary, bonus, incentive and equity compensation);

review director compensation levels and practices, and recommend, from time to time, changes in such compensation levels and practices;

review our compensation, incentive compensation and equity-based plans and recommend, from time to time, changes in such compensation levels and practices to the Board;

review and discuss with our management the Compensation Discussion and Analysis to be included in our annual proxy statement, annual report on Form 10-K or information statement, as applicable, and make a recommendation as to whether it should be included therein;

conduct an annual review of the adequacy of its charter and recommend any proposed changes to the Board for its approval; and

perform any other activities consistent with our Certificate of Incorporation, Bylaws and governing law as the Compensation Committee or the Board deems appropriate.

During 2021, the Compensation Committee held four meetings, including regularly scheduled and special meetings.

Role and Responsibilities

The Compensation Committee is responsible for reviewing and approving the base salary increases (other than any annual base salary increases contemplated by existing employment agreements) and bonus levels of our executive officers, including our named executive officers, evaluating the performance of such executives and reviewing any related matters. Equity and other forms of compensation for our executive officers, including our named executive officers, are also considered by the Compensation Committee. In considering and determining our executive compensation program, the Compensation Committee primarily relies upon the following factors:

Peer Group Data. The Compensation Committee has consistently sought to structure our executive compensation program to provide amounts and forms of compensation to our executive officers that are generally commensurate with those paid to executive officers with comparable duties and responsibilities at companies that provide senior living and healthcare services and companies that have significant real estate ownership of residential or senior living communities that the Compensation Committee, in consultation with our independent compensation consultant and senior management, periodically determines to be the most directly comparable to the Company.

Third Party Industry Surveys and Compensation Consultants. As part of its ongoing efforts to provide independent oversight and review of our executive compensation programs, the Compensation Committee periodically reviews information compiled by third parties with respect to the executive compensation practices of other companies in our industry. The Compensation Committee reviews such information for purposes of obtaining a general understanding of current compensation practices of companies in our peer group and general industry. The information reviewed is part of a larger competitive analysis and does not mandate a particular decision regarding the compensation opportunities of our named executive officers. The Compensation Committee is also authorized to engage independent compensation consultants from time to time to review our executive compensation arrangements. See “—Role of Independent Compensation Consultant” below.

Other Factors. Other key factors beyond compensation market data also affect the Compensation Committee’s judgment with respect to our executive compensation program. These factors include our financial and stock performance, and the contribution of each executive officer relative to his or her individual responsibilities and capabilities, the individual’s experience in their role and tenure with the Company, internal alignment with the executive team and retention concerns, among other relevant factors.

Role of Management. The Compensation Committee has also relied in part upon the input and recommendations of our CEO when considering annual increases to base salaries for our other executive

officers, the annual establishment of our Incentive Compensation Plan (which aligns with the Company’s business plan), and whether to grant long-term incentive awards to our other executive officers, and if so, in what forms and amounts. The Compensation Committee typically takes into account these recommendations from our CEO.

In fulfilling its responsibilities and duties with respect to the compensation of our directors, the Compensation Committee periodically reviews the compensation paid to the non-employee directors of the companies in our peer group, and may recommend to the Board adjustments to our director compensation levels and practices so as to remain competitive with the companies in our peer group.

Role of Independent Compensation Consultant

Pursuant to its charter, the Compensation Committee may retain such compensation consultants, outside counsel and other advisors as it may deem appropriate in its sole discretion and it has the sole authority to approve related fees and other retention terms. From time to time, the Compensation Committee has engaged third parties to compile statistical information with respect to the executive compensation practices of other comparable public companies and has retained independent compensation consultants to review the Company’s compensation arrangements for certain of its named executive officers and its independent directors.

The Compensation Committee engaged Meridian Compensation Partners, LLC (“Meridian”) as its independent consultant to review the Company’s 2021 compensation arrangements for certain of its executive officers and its independent directors, including an analysis of both the competitive market and the design of the compensation arrangements. Meridian also assisted the Compensation Committee with a variety of matters, including the design of the annual and long-term incentive program and its impact on officer retention, and an annual risk assessment of our compensation policies and practices applicable to our executive officers and other employees. Meridian reported its findings to the Compensation Committee to help inform the Compensation Committee’s decision-making on executive officer compensation for 2021. The Compensation Committee recognizes that it is essential to receive objective advice from its external advisors. Consequently, the Compensation Committee is solely responsible for retaining and terminating its consultants, Meridian reported directly to the Compensation Committee, and Meridian did not provide any other services to the Company during fiscal 2021.

The fees payable by the Company to Meridian for its services as of December 31, 2021 were approximately $73,753. The Compensation Committee evaluated the independence of Meridian and concluded that Meridian was independent and presented no conflict of interest.

Board of Directors’ Leadership Structure

In 2010, our Board separated the roles of Chairman of the Board and Chief Executive Officer by electing a non-executive, independent director as Chairman of the Board. Since November 2021, Mr. Johnson has served as non-executive Chairman of the Board. The separation of the roles was implemented to allow our Chief Executive Officer to continue to focus his or her efforts on the successful management of the Company while allowing our independent Chairman to focus his efforts on the continued development of a high-performing Board, including (1) ensuring the Board remains focused on the Company’s long-term strategic plans, (2) working with Company management to ensure the Board continues to receive timely and adequate information, (3) coordinating activities of the committees of the Board, and (4) ensuring effective stakeholder communications. The Board believes, due to the continued leadership and experience provided by these two individuals, that having separate positions is the appropriate leadership structure for the Company at this time and demonstrates our commitment to good corporate governance.

Board of Directors’ Role in Risk Oversight

Our Company, like others, faces a variety of enterprise risks, including credit risk, liquidity risk, and operational risk. In fulfilling its risk oversight role, the Board focuses on the adequacy of the Company’s risk management process and overall risk management system. The Board believes an effective risk management system will (1) adequately identify the material risks that the Company faces in a timely manner, (2) implement appropriate risk management strategies that are responsive to the Company’s risk profile and specific material risk exposures, (3) integrate consideration of risk and risk management into business decision-making throughout the Company, and (4) include policies and procedures that adequately transmit necessary information with respect to material risks to senior executives and, as appropriate, to the Board or relevant committee.

The Audit Committee has been designated to take the lead in overseeing risk management at the Board level. Accordingly, the Audit Committee schedules time for periodic reviews of risk management, in addition to its other duties. In this role, the Audit Committee receives information from management and other advisors, and strives to generate serious and thoughtful attention to the Company’s risk management process and system, the nature of the material risks the Company faces, and the adequacy of the Company’s policies and procedures designed to respond to and mitigate these risks.

In addition, the Nominating and Corporate Governance Committee is responsible under its charter for reviewing with management and assisting and advising the Board with respect to resident care and services. This risk management and risk assessment includes management compliance with regulatory requirements related to resident care and services and other related matters, including meeting the Company’s expectations for providing quality care and services to its residents.

Although the Board’s primary risk oversight has been assigned to the Audit Committee, the full Board also periodically receives information about the Company’s risk management system and the most significant risks that the Company faces. This is principally accomplished through the Audit Committee’s discussions with the full Board and summary versions of the briefings provided by management and advisors to the Audit Committee.

In addition to the formal compliance program, the Board and the Audit Committee encourage management to promote a corporate culture that understands risk management and incorporates it into the overall corporate strategy and day-to-day business operations. The Company’s risk management structure also includes an ongoing effort to assess and analyze the most likely areas of future risk for the Company. As a result, the Board and Audit Committee periodically ask the Company’s executives to discuss the most likely sources of material future risks and how the Company is addressing any significant potential vulnerability.

Director Nominations

The Nominating and Corporate Governance Committee is responsible under its charter for identifying and recommending qualified candidates for election to the Board. In addition, stockholders who would like to recommend a candidate for election to the Board may submit the recommendation to the chairman of the Nominating and Corporate Governance Committee, in care of David R. Brickman, our Senior Vice President, General Counsel and Secretary. Any recommendation must include name, contact information, background, experience and other pertinent information on the proposed candidate and must be received in writing by November 15th of a calendar year for consideration by the Nominating and Corporate Governance Committee for the annual meeting of our stockholders in the immediately following calendar year.

Although the Nominating and Corporate Governance Committee is willing to consider candidates recommended by our stockholders, it has not adopted a formal policy with regard to the consideration of any director candidates recommended by our stockholders. The Nominating and Corporate Governance Committee believes that a formal policy is not necessary or appropriate because of the small size of the Board and because the current Board already has a diversity of business background and industry experience.

The Nominating and Corporate Governance Committee does not have specific minimum qualifications that must be met by a candidate for election to the Board in order to be considered for nomination by the Nominating and Corporate Governance Committee. In identifying and evaluating nominees for director, the Nominating and Corporate Governance Committee considers each candidate’s qualities, experience, background and skills, as well as any other factors that the candidate may be able to bring to the Board. The process is the same whether the candidate is recommended by a stockholder, another director, management or otherwise. Although the Nominating and Corporate Governance Committee does not have a formal diversity policy in place for the director nomination process, an important factor in the Nominating and Corporate Governance Committee’s consideration and assessment of a candidate is the diversity of the candidate’s viewpoints, professional experience, education and skill set. The Nominating and Corporate Governance Committee does not pay a fee to any third party for the identification of candidates, but it has paid fees in the past to third parties for background checks on candidates.

With respect to this year’s nominees for director, Messrs. Brooks, Harris and Johnson currently serve as directors of the Company.

Investor Rights Agreement

In November 2021, we entered into the Investor Rights Agreement with the Conversant Investors and Silk, which Investor Rights Agreement pertains to, among other things, the appointment of (i) a certain number of directors nominated by Conversant Fund A (“Conversant Representatives”) to the Board based upon the ownership percentage in the Company of the Conversant Investors and their affiliates and permitted transferees, and (ii) two directors nominated by Silk (the “Silk Representatives”) for so long as Silk and its affiliates beneficially own at least five percent of the outstanding shares of common stock of the Company on an as-converted basis. Additionally, pursuant to the Investor Rights Agreement, for so long as the Conversant Investors and their affiliates and permitted transferees collectively satisfy a certain percentage of beneficial ownership in the Company, Conversant Fund A will be entitled to designate the chairperson of the Board. Pursuant to the terms of the Investor Rights Agreement, Conversant Fund A is entitled to designate four individuals to be appointed to the Board and the Chairman of the Board and Silk is entitled to designate two individuals to be appointed to the Board. Conversant Fund A designated Benjamin P. Harris, David W. Johnson, Max J. Levy, and Elliot R. Zibel as the Conversant Representatives with Mr. Johnson as the Chairman of the Board and Silk designated Noah R. Beren and Shmuel S.Z. Lieberman as the Silk Representatives, and such individuals were appointed to the Board in November 2021.

Pursuant to the Investor Rights Agreement, the Conversant Investors agreed to certain standstill provisions. Among other things, and subject to certain exceptions, the standstill prevents the Conversant Investors from: (i) engaging in certain proxy contest activities, (ii) acquiring any securities of the Company, or (iii) taking any actions to change the composition of the Board (other than in respect of Conversant Representatives), in each case, for a period of 18 months from the date of the Investor Rights Agreement.

The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Investor Rights Agreement, a copy of which the Company filed with the SEC as Exhibit 10.1 to a Current Report on Form 8-K on November 4, 2021.

Code of Business Conduct and Ethics

The Board has adopted a Code of Business Conduct and Ethics governing all of our employees, including our Chief Executive Officer, Chief Financial Officer, our principal accounting officer and corporate controller. A copy of this Code of Business Conduct and Ethics is available in the “Corporate Governance Documents” section of the “Investor Relations” section of our website at www.sonidaseniorliving.com. We intend to make all required disclosures concerning any amendments to, or waivers from, this Code of Business Conduct and Ethics on our website.

Anti-Hedging and Anti-Pledging Policies

As part of our Policy on Insider Trading, directors, officers and employees are prohibited from engaging in hedging transactions with respect to our securities. In addition, directors, officers and other employees are prohibited from holding our securities in a margin account and are also prohibited from pledging our securities as collateral for a loan unless such pledging has been disclosed to, and pre-approved by, the Board.

Website

Our Internet website, www.sonidaseniorliving.com, contains an Investor Relations section, which provides links to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, SEC stock ownership reports, amendments to those reports and filings, Code of Business Conduct and Ethics, Corporate Governance Guidelines, Director Independence Policy and charters of the Nominating and Corporate Governance Committee, Compensation Committee and Audit Committee of the Board. These documents are available in print, free of charge, to any stockholder who requests a copy as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The materials on our website are not incorporated by reference into this Proxy Statement and do not form any part of the materials for solicitation of proxies.

Communication with Directors

Correspondence from stockholders and other interested parties may be sent to our directors, including our non-management directors, individually or as a group, in care of David W. Johnson, the Chairman of our Board, with a copy to David R. Brickman, Senior Vice President, General Counsel and Secretary, at, our principal executive offices 16301 Quorum Drive, Suite 160A, Addison, Texas 75001.

All communications received as set forth above will be opened by the Chairman and Senior Vice President, General Counsel and Secretary for the sole purpose of determining whether the contents represent a message to our directors. Appropriate communications other than advertising, promotions of a product or service, or patently offensive material will be forwarded promptly to the addressee.

EXECUTIVE OFFICERS

The following table sets forth certain information concerning each of the Company’s executive officers, other than Ms. Lody. Information concerning Ms. Lody is set forth above under “Election of Directors—Directors Continuing in Office Until the 2023 Annual Meeting.”

Name

Age

Position(s) with the Company

Brandon M. Ribar

41

Executive Vice President and Chief Operating Officer

David R. Brickman

64

Senior Vice President, Secretary and General Counsel

Jeremy D. Falke

48

Senior Vice President—Human Resources

Michael C. Fryar

45

Senior Vice President and Chief Revenue Officer

Carole J. Burnell

53

Vice President—Operations

Brandon M. Ribar joined the Company in September 2019 and is currently the Executive Vice President and Chief Operating Officer. Prior to joining the Company, Mr. Ribar served as an executive healthcare consultant primarily focused on improving existing operations and expanding continuing care retirement communities for multiple investment platforms and operators since 2018. From 2014 through 2018, he served as the Senior Vice President, Operations of Golden Living, a post-acute healthcare provider. Prior to serving in such capacity, Mr. Ribar served Golden Living in various roles including Senior Vice President, Operational Finance and Strategy and Senior Vice President, Corporate Strategy and Business Development. Prior to Golden Living, Mr. Ribar served as Vice President of Fillmore Capital Partners from 2004 through 2009. Mr. Ribar received a BSC in Operations and Management Information Systems from Santa Clara University.

David R. Brickman is currently the Senior Vice President, Secretary, and General Counsel of the Company. He served as Vice President and General Counsel of the Company and its predecessors since July 1992 and has served as Secretary of the Company since May 2007. From 1989 to 1992, Mr. Brickman served as in-house counsel with LifeCo Travel Management Company, a corporation that provided travel services to U.S. corporations. Mr. Brickman earned a Juris Doctor and Masters of Business Administration from the University of South Carolina and a Masters in Health Administration from Duke University. He currently serves on the Board of Advisors for the Southern Methodist University Corporate Counsel Symposium. He is also a member of the National Center for Assisted Living In-house Counsel Roundtable Task Force, as well as the Long-Term Care Risk Legal Forum. Mr. Brickman has either practiced law or performed in-house counsel functions for 33 years.

Jeremy D. Falke joined the Company as Senior Vice President—Human Resources in February 2018. Mr. Falke held various positions within Tenet Healthcare Corporation (“Tenet”) from November 2004 to February 2018, serving most recently as the Vice President, Talent, Culture and Performance Systems in Dallas. In this role, he was responsible for all talent planning, development, and cultural programming and transformation for an organization with over 75 acute-care hospitals and 450 outpatient facilities, employing more than 125,000 people. Prior to this role, Mr. Falke served as the Senior Director, Strategic Operations, Analytics and Reporting in Dallas and as the Chief Human Resources Officer for Creighton University Medical Center, which was then owned by Tenet in Omaha, Nebraska. Mr. Falke received a Bachelor of Science in Business Management from University of Phoenix in Scottsdale, and a Masters of Business Administration with a concentration in Healthcare Management from the University of Nebraska in Omaha.

Michael C. Fryar joined the Company as Chief Revenue Officer in February 2019. His 20 years of experience focusing on brands in complex, multi-channel environments includes leadership positions in medical device and marketing agency settings, with the majority of his career focused in senior healthcare. Prior to joining the Company, Mr. Fryar served as Vice President of GN Hearing North America, where he was part of a leadership team responsible for seven consecutive years of above-market growth and expansion across multiple channels and brands. Prior to GN Hearing, Mr. Fryar served as Senior Director, Marketing at Starkey Hearing Technologies from 2006 to 2012. From 1998 to 2006, he served as an account director at marketing agency Colle McVoy, specializing in digital and traditional marketing, advertising and public relations. Mr. Fryar received a BA in Communications Studies with a minor in Economics Management from Gustavus Adolphus College.

Carole J. Burnell is currently the Vice President – Operations of the Company. She served as the Regional Operations Manager in the Dallas Region of the Company from January 2004 to March 2019. Ms. Burnell has over 22 years of senior living industry experience and has held a variety of leadership roles during that time. She started her career as an Executive Director with Assisted Living Concepts, and has since served in both large publicly traded and small privately held senior living companies with multi-community oversight responsibilities. She earned a BBA degree with a concentration in Accounting from West Texas A&M University.

EXECUTIVE COMPENSATION TABLES

Summary Compensation Table

The following table summarizes the compensation earned by our named executive officers in 2021 and 2020. Please note that total compensation, as reported in the Summary Compensation Table below and calculated under SEC rules, reflects pre-tax amounts and several items that are driven by accounting assumptions on incentive awards that have not yet been earned, including awards that vest over a period of time and/or are subject to the satisfaction of various performance targets. Therefore, it is not necessarily reflective of the compensation our named executive officers actually realized for such years.

Name and Principal Position

 Year  Salary  Bonus  Stock
Awards(1)
  Option
Awards
  Non-Equity
Incentive Plan
Compensation(2)
  All Other
Compensation(3)
  Total 

Kimberly S. Lody,

  2021  $738,896  $1,583,763(4)  $2,101,772     $391,749  $600  $4,816,780 

President and Chief Executive Officer

  2020  $725,000  $362,500        $299,063  $3,457  $1,390,020 

Brandon M. Ribar,

  2021  $402,487  $725,000(4)  $1,499,010     $137,542  $600  $2,764,639 

Executive Vice President and Chief Operating Officer

  2020  $400,000  $200,000        $63,000     $663,000 

David R. Brickman,

  2021  $344,498  $533,064(4)  $917,552     $83,793  $600  $1,879,507 

Senior Vice President, General Counsel and Secretary

  2020  $341,161  $394,676        $57,591  $5,170  $798,598 

(1)

Amounts for 2021 reflect the grant date fair value of the respective equity awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“ASC 718”), including, with respect to performance-based shares, the grant date fair value of the performance shares based on the probable outcome of the performance conditions as of the date of grant (rather than the maximum potential value of the award). Assumptions used in the calculation of these amounts are included in footnote 11 to our audited financial statements for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on April 15, 2022.

(2)

Amounts in this column for 2021 reflect the cash performance incentive received by Ms. Lody and Messrs. Ribar and Brickman under our Fiscal 2021 Incentive and Retention Plan. See “—Fiscal 2021 Incentive and Retention Plan—Performance Bonuses” below for additional information.

(3)

The amounts in this column for 2021 reflect a monthly stipend of $50 received by each of our named executive officers to compensate them for working remotely.

(4)

The amounts in this column for 2021 reflect the retention awards earned by Ms. Lody and Messrs. Ribar and Brickman and for fiscal 2021. See “—Fiscal 2021 Incentive and Retention Plan —Retention Awards” below for additional information. In addition, the amounts include (i) the remaining portion of such named executive officer’s retention award granted in 2020, which equaled 50% of such named executive’s then current base salary and was subject to such named executive officer remaining continuously employed by the Company through March 15, 2021, and (ii) the first portion of a retention award granted to our named executive officers in connection with the closing of the Conversant transactions (the “Conversant Closing Retention Awards”), which was paid on November 15, 2021 ($813,450, $300,000 and $170,580 for Ms. Lody and Messrs. Ribar and Brickman, respectively). The remaining portion of the Conversant Closing Retention Awards ($813,450, $300,000 and $170,580 for Ms. Lody and Messrs. Ribar and Brickman, respectively) is payable on May 15, 2022 provided such named executive officer remains continuously employed by the Company through such date.

Employment Agreements

Kimberly S. Lody

We entered into an employment agreement with Ms. Lody in January 2019. Pursuant to Ms. Lody’s employment agreement, Ms. Lody serves as our President and Chief Executive Officer. Ms. Lody’s employment agreement was for an initial term of three years and automatically renews for additional one-year periods in the event that we do not, or Ms. Lody does not, provide written notice to the other party of their intent not to renew such term at least 30 days prior to the expiration of the then-current term. Ms. Lody’s employment agreement provides that our Board of Directors will nominate Ms. Lody for reelection to the Board at the expiration of each term of office, and that Ms. Lody will serve as a member of our Board for each period for which she is so elected.

Pursuant to Ms. Lody’s employment agreement, she receives an annual base salary of not less than $725,000 and is eligible to receive an annual performance bonus targeted at60 but not lessmore than 110% of her base salary. Ms. Lody is also eligible to receive equity awards under our annual equity incentive award program in effect for our other senior executives, as determined by90 days before the Compensation Committee. Ms. Lody’s employment agreement also entitles her to certain severance payments and benefits in the event she is terminated by us without “Cause” or by Ms. Lody for “Good Reason” (including in connection with a “Change in Control”), as described more fully in Ms. Lody’s employment agreement.

The foregoing description of Ms. Lody’s employment agreement does not purport to be complete and is qualified in its entirety by the reference to the full text of Ms. Lody’s employment agreement, which is included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 8, 2019.

Brandon M. Ribar

We entered into an employment agreement with Mr. Ribar in September 2019. Pursuant to Mr. Ribar’s employment agreement, Mr. Ribar serves as our Executive Vice President and Chief Operating Officer. Mr. Ribar’s employment agreement was for an initial term of one year and is subject to extension by the mutual written consentscheduled date of the Company and Mr. Ribar.

Pursuant to Mr. Ribar’s employment agreement, he receives an annual base salarymeeting, regardless of not less than $400,000 and is eligible to receive a performance bonus as determined by the Compensation Committee. Mr. Ribar’s employment agreement also entitles him to certain severance payments and benefits in the event he is terminated by us without “Cause”any postponement, deferral or by Mr. Ribar for “Good Reason” (including in connection with a “Fundamental Change”), as described more fully in Mr. Ribar’s employment agreement.

The foregoing descriptionadjournment of Mr. Ribar’s employment agreement does not purport to be complete and is qualified in its entirety by the reference to the full text of Mr. Ribar’s employment agreement, which is included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 10, 2019.

David R. Brickman

In March 2021, we entered into a new employment agreement with Mr. Brickman that terminated and replaced his then-existing employment agreement. Pursuant to Mr. Brickman’s employment agreement, Mr. Brickman serves as our Senior Vice President, General Counsel and Secretary, he receives an annual base salary of not less than $335,000 and he is eligible to receive an annual performance bonus targeted at not less than 50% of his base salary. Mr. Brickman’s employment agreement also entitles him to certain severance payments and benefits in the event he is terminated by us without “Cause” or by Mr. Brickman for “Good Reason” (including in connection with a “Change in Control”), as described more fully in Mr. Brickman’s employment agreement.

The foregoing description of Mr. Brickman’s employment agreement does not purport to be complete and is qualified in its entirety by the reference to the full text of Mr. Brickman’s employment agreement, which is included as Exhibit 10.28 to the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2021.

Fiscal 2021 Incentive and Retention Plan

On March 29, 2021, our Board of Directors approved an incentive and retention plan for fiscal year 2021 (the “Fiscal 2021 Incentive and Retention Plan”) pursuant to which our named executive officers and certain other executive officers (each, a “Participant” and, collectively, the “Participants”) had the opportunity to earn cash performance bonuses (the “Performance Bonuses”) and retention awards (the “Retention Awards”) for fiscal year 2021.

Retention Awards

With respect to the Retention Awards, each Participant was eligible to receive cash payments equal to 25%, 18.8% and 12.5% of their annual base salary for the first, second and third quarters of fiscal year 2021, respectively, subject to the Participant’s continued employment with us through the applicable payment dates for the Retention Awards (August 15, 2021 with respect to the first and second quarters of fiscal year 2021 and November 15, 2021 with respect to the third quarter of fiscal year 2021). If the Participant did not remain continuously employed with us through such dates, then the portion of the Retention Award subject to continuous employment as of such date would be forfeited, except that, if any Participant’s employment is terminated (i) by us without “Cause” (and other than due to the Participant’s death or “Disability”), or (ii) upon or following a “Change in Control” (each such term as defined in the 2019 Omnibus Stock and Incentive Plan for Sonida Senior Living, Inc., as amended (the “2019 Plan”)), in each case, prior to November 15, 2021, then the aggregate amount of the Retention Awards would be paid to such Participant.

The table below shows the Retention Awards our named executive officers were eligible to receive under our Fiscal 2021 Incentive and Retention Plan. As each of our named executive officers remained continuously employed with us through each of the applicable payment dates, each named executive officer received the full amount of the Retention Award set forth in the “Total” column of the table below.

Named Executive Officer

  First
Quarter
   Second
Quarter
   Third
Quarter
   Total 

Kimberly S. Lody

  $181,250   $135,938   $90,625   $407,813 

Brandon M. Ribar

  $100,000   $75,000   $50,000   $225,000 

David R. Brickman

  $85,290   $63,968   $42,645   $191,903 

Performance Bonuses

Each Participant was eligible to earn a target Performance Bonus equalmeeting to a percentage of their annual base salary for fiscal year 2021. Pursuant to the terms of their respective employment agreements, the targeted Performance Bonus for our President and CEO, Executive Vice President and Chief Operating Officer, and Senior Vice President, Secretary and General Counsel was equal to 110%, 70% and 50%, respectively, of their annual base salary for fiscal 2021. One-third of the targeted Performance Bonus was payable for each of the second, third and fourth quarters of fiscal year 2021 in the event the Company satisfied certain revenue and net operating income (“NOI”) performance targets with respect to such quarter. The amount of the Performance Bonus payable was divided equally between each of the two performance targets (i.e., 50% each). Achievement of the threshold level of performance for each quarterly performance target (95% of the targeted level of performance) would result in 50% of the portion of the Performance Bonus subject to such performance target being earned by the Participant and achievement of the maximum level of performance for each quarterly performance target (105% of the targeted level of performance) would result in 150% of the portion of the Performance Bonus subject to such performance target being earned by the Participant. Performance below threshold level would result in no payout for the applicable performance metric and payouts were capped at the

maximum level for performance that exceeds maximum goals. Payouts for any performance between threshold, target and maximum levels were interpolated.

The table below shows the threshold, target and maximum performance targets for Performance Bonuses under our Fiscal 2021 Incentive and Retention Plan.

Target

  Payout as a
Percentage of
Target
  Second
Quarter
  Third
Quarter
  Fourth
Quarter

Revenue

  Threshold (50%)  $45,175,854  $46,192,556  $47,285,453
  Target (100%)  $47,553,531  $48,623,743  $49,774,161
  Max (150%)  $49,931,208  $51,054,930  $52,262,869

NOI

  Threshold (50%)  $11,878,164  $13,472,212  $13,834,846
  Target (100%)  $12,503,331  $14,181,276  $14,562,996
  Max (150%)  $13,128,498  $14,890,340  $15,291,146

The table below shows our actual results with respect the Performance Bonuses under our Fiscal 2021 Incentive and Retention Plan and the corresponding payout factors, if any, relating to each corporate goal.

   Second Quarter  Third Quarter  Fourth Quarter 

Target

  Result   Payout
Factor
  Result   Payout
Factor
  Result   Payout
Factor
 

Revenue

  $46,628,241    80.5 $49,327,796    114.5 $49,759,799    99.7

NOI

  $7,935,860    0 $9,458,858    0 $8,771,095    0

Based upon the foregoing, the table below summarizes the Performance Bonuses earned by each of our named executive officers under our Fiscal 2021 Incentive and Retention Plan. The payout amounts relate to our achievement of the quarterly revenue performance targets discussed above. As we did not achieve any of the quarterly performance targets relating to NOI during 2021, no Performance Bonuses were paid to our named executive officers relating to such performance targets.

   Second Quarter   Third Quarter   Fourth Quarter     

NEO

  Payout
Factor
  Amount   Payout
Factor
  Amount   Payout
Factor
  Amount   Total 

Kimberly S. Lody

   40.3 $107,054    57.2 $152,162    49.9 $132,533   $391,749 

Brandon M. Ribar

   40.3 $37,586    57.2 $53,424    49.9 $46,532   $137,542 

David R. Brickman

   40.3 $22,898    57.2 $32,547    49.9 $28,348   $83,793 

Equity Compensation Arrangements

In addition to the employment agreements described above, our named executive officers are entitled to receive payments under the terms of our equity compensation plans and equity award agreements upon a “change in control” and the termination of the named executive officer’s employment due to death or disability.

2019 Omnibus Stock and Incentive Plan

In the event of a “change in control,” our 2019 Plan provides for the following treatment of awards unless otherwise provided in an award agreement:

Unless converted, assumed, or replaced by a successor or survivor corporation, or a parent or subsidiary thereof, all awards will become fully exercisable, all forfeiture restrictions will lapse, and, following the consummation of such change in control, all such awards will terminate and cease to be outstanding.

The number or value of any performance-based award or other award that is based on performance criteria or performance goals that will become fully earned, vested, exercisable and free of forfeiture restrictions will not exceed the greater of (i) such number or value determined by the actual performance attained during the applicable performance period to the time of the change in control or (ii) such number or value that would be fully earned, vested, exercisable and free of forfeiture restrictions had 100% of the target level of performance been attained for the entire applicable performance period without regard to the change in control.

If awards are assumed or continued after a change in control, the Compensation Committee may provide that all or a portion of such awards will become fully exercisable and all forfeiture restrictions will lapse immediately upon the involuntary termination of the participant’s employment or service within a designated period (not to exceed 24 months) following the effective date of such change in control.

Upon a change in control, the Compensation Committee may cause any and all awards outstanding to terminate at a specific time in the future, and will give each participant the right to exercise such awards during a period of time as the Compensation Committee, in its sole and absolute discretion, will determine.

The portion of any incentive stock option accelerated in connection with a change in control will remain exercisable as an incentive stock option only to the extent the applicable $100,000 limitation is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option will be exercisable as a non-qualified stock option under the U.S. federal tax laws.

2007 Omnibus Stock and Incentive Plan

In the event of a “change in control,” our 2007 Omnibus Stock and Incentive Plan, as amended, provides for the following treatment of awards unless otherwise provided under the terms of an award or by the Compensation Committee prior to such transaction:

all outstanding awards (except performance awards which will be governed by their express terms) will become fully exercisable, nonforfeitable, or the restricted period will terminate, as the case may be; and

the Compensation Committee will have the right to cash out some or all outstanding non-qualified stock options, stock appreciation rights and shares of restricted stock on the basis of the highest price per share paid in any transaction reported on the NYSE or paid or offered in any bona fide transaction related to a “change in control” during the immediately preceding 60-day period, in each case as determined by the Compensation Committee (except that the cash out for stock appreciation rights related to incentive stock options will be based on transaction reported for the date on which the holder exercises the stock appreciation rights or, if applicable, the date on which the cash out occurs).

Time-Based Restricted Stock Award Agreements

When our named executive officers are awarded shares of restricted stock with time-based vesting provisions, each of them enters into a restricted stock award agreement with us. These restricted stock award agreements generally provide that, if the holder’s employment with us is terminated for any reason before the vesting date for the restricted shares, the restricted shares that have not previously vested will, automatically and without notice, terminate and be permanently forfeited as of such date, except that all unvested shares will vest if the holder’s employment terminates on or after the first anniversary of the grant date due to the holder’s death or disability.

In the event of a change in control, shares of time-based restricted stock will not automatically vest;later date; provided, however, that (i) if the Compensation Committee has made a provision for the substitution, assumption, exchangeless than 70 days’ notice or other continuation of such award in connection with the change in control, then in the event that the holder’s employment is terminated (A) by us due to death, disability or retirement following the

change in control, then the unvested portion of the award will immediately fully vest, or (B) by us other than for “Cause” or by the holder for “Good Reason,” in each case within one year following the change in control, the unvested portion of the award will immediately fully vest; or (ii) if the Compensation Committee has not made a provision for the substitution, assumption, exchange or other continuation of such award in connection with the change in control, the unvested portion of the award will fully vest immediately prior to the change in control.

Performance-Based Restricted Stock Award Agreements

When our named executive officers are awarded shares of performance-based restricted stock, each of them enters into a performance award agreement with us. These performance award agreements generally provide that, (1) if the holder’s employment with us is terminated for any reason before the vesting date for the performance shares, the performance shares that have not previously vested will, automatically and without notice, terminate and be permanently forfeited as of such date, and (2) the holder’s right to receive the specified percentage of performance shares that do not vest as a result of our failure to achieve the applicable performance measures will be automatically terminated and permanently forfeited; provided, that if a named executive officer’s continuous service is terminated by the Company due to death or disability, the unvested performance shares will remain outstanding and a pro-rated portion thereof shall vest if the applicable performance target is satisfied during the performance period.

In the event of a change in control or an event which results in our common stock no longer being readily tradeable on an established securities market and provided the named executive officer remains in continuous service with the Company aspublic disclosure of the date of the meeting is given or made to stockholders, the notice must be delivered or received no later than the close of business on the tenth day following the earlier of (1) the day on which such transaction, allnotice of the date of meeting was mailed or (2) the day on which such public disclosure was made. The notice of a stockholder proposal or a portion of the performance shares may vest upon the closing of such transaction depending on the value of the consideration received by our shareholders in connection with the transaction.

2021 Outstanding Equity Awards at Fiscal Year-End

The following table sets forthdirector nomination must also contain specified information and conform to certain information with respect to our named executive officers’ outstanding stock options and restricted stock awards as of December 31, 2021.

  Option Awards  Stock Awards 

Name

 Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
  Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
  Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
  Option
Exercise
Price
($)
  Option
Expiration
Date
  Number
of Shares
or Units
of Stock
That
Have Not
Vested
(#)
  Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(1)
  Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not  Vested
(#)
  Equity
Incentive
Plan Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(1)
 

Kimberly S.
Lody

  6,479   3,337(a)      111.90   1/7/2029             
                 11,484(b)   327,179       
                 45,305(c)   1,290,739       
                       21,361(d)   608,575 

Brandon M.
Ribar

                 3,567(e)   101,624       
                 18,424(c)   524,900       
                       38,550(d)   1,098,290 

David R.
Brickman

                 2,776(f)   79,088       
                 10,269(c)   292,564       
                       25,700(d)   732,193 

(1)

Calculated by reference to the closing price for shares of our common stock on the NYSE on December 31, 2021, which was $28.49 per share.

(a)

Represents stock option to purchase 9,816 shares of common stock granted on January 7, 2019, which vested in installments of 33%, 33% and 34% on January 7, 2020, January 7, 2021 and January 7, 2022, respectively.

(b)

Represents the remaining shares of restricted stock (third tranche) granted on January 7, 2019, which vested in installments of 33%, 33% and 34% on January 7, 2020, January 7, 2021 and January 7, 2022, respectively, and shares of performance-based restricted stock granted on January 7, 2019 that were converted into time-based shares of restricted stock in connection with closing of the Conversant transactions and fully vested on January 7, 2022.

(c)

Represents shares of restricted stock granted on March 24, 2021, which vest in installments of 33%, 33% and 34% on March 24, 2022, March 24, 2023 and March 24, 2024, respectively, and shares of performance-based restricted stock granted on March 24, 2021 that were converted into time-based shares of restricted stock in connection with the closing of the Conversant transaction and are scheduled to fully vest on March 24, 2024.

(d)

Represents shares of performance-based restricted stock granted on November 15, 2021, which vest subject to the satisfaction of the target performance objective.

(e)

Represents the remaining shares of restricted stock (third tranche) granted on September 10, 2019, which vested in installments of 33%, 33% and 34% on September 10, 2020, September 10, 2021 and September 10, 2022, respectively, and shares of performance-based restricted stock granted on September 10, 2019 that were converted into time-based shares of restricted stock in connection with closing of the Conversant transactions and fully vested on January 7, 2022.

(f)

Represents the remaining shares of restricted stock (third tranche) granted on May 14, 2019, which vest in installments of 33%, 33% and 34% on May 14, 2020, May 14, 2021 and May 14, 2022, respectively, and shares of performance-based restricted stock granted on May 14, 2019 that were converted into time-based shares of restricted stock in connection with closing of the Conversant transactions and are scheduled to fully vest on May 14, 2022.

2021 DIRECTOR COMPENSATION

The following table summarizes the compensation earned by our non-employee directors in 2021.

Name*

  Fees Earned or
Paid in Cash ($)(1)
   Stock
Awards
($)(2)
   Option
Awards ($)
   All Other
Compensation ($)
   Total ($) 

Noah R. Beren(3)

  $10,000               $10,000 

Philip A. Brooks

  $175,000   $74,996           $249,996 

Benjamin P. Harris(3)

  $10,833               $10,833 

David W. Johnson(3)

  $19,167               $19,167 

Jill M. Krueger

  $83,333   $74,996           $158,329 

Max J. Levy(3)

                    

Shmuel S.Z. Lieberman(3)

  $11,667               $11,667 

Elliot R. Zibel(3)

  $10,000               $10,000 

Ed A. Grier(4)

  $66,667   $74,996           $141,663 

E. Rodney Hornbake(4)

  $52,500   $74,996           $127,496 

Ross B. Levin(4)

  $158,333   $74,996           $233,329 

Steven T. Plochocki(4)

  $56,250   $74,996           $131,246 

Michael W. Reid(4)

  $187,500   $74,996           $262,496 

During 2021, we did not maintain any pension or deferred compensation arrangements for our directors.

(1)

Represents an annual retainer fee and compensation for attendance at Board and committee meetings during 2021. See “—Compensation of Directors During 2021” below for more information.

(2)

Amounts reflect the aggregate grant date fair value of the equity awards computed in accordance with ASC 718, and represents 1,422 shares of restricted stock granted pursuant to the 2019 Plan on May 19, 2021 to each of our non-employee directors serving at such time, which vested in full in November 2021 in connection with the closing of the Conversant private placement and rights offering transactions.

(3)

Messrs. Beren, Harris, Johnson, Levy, Lieberman and Zibel were appointed to the Board in November 2021 pursuant to the Investor Rights Agreement. Mr. Levy does not receive fees for his service as a director of the Company pursuant to an arrangement between Mr. Levy and Conversant.

(4)

Dr. Hornbake and Messrs. Grier, Levin, Plochocki and Reid resigned from the Board in November 2021 in connection with the appointment of the Conversant Representatives and the Silk Representatives to the Board pursuant to the Investor Rights Agreement. The resignations of Dr. Hornbake and Messrs. Grier, Levin, Plochocki and Reid were not due to any disagreement with management or the Board.

Compensation of Directors During 2021

For their services to us, our non-employee directors in 2021 each received an annual retainer of $55,000 (in addition to the committee retainers and meeting fees discussed below). In addition, the independent Chairman of our Board, the Chairman of the Audit Committee, the Chairman of the Nominating and Corporate Governance Committee, the Vice Chairman of the Nominating and Corporate Governance Committee, and the Chairman of the Compensation Committee, each received an additional annual retainer of $50,000, $20,000, $10,000, $8,000 and $15,000, respectively, for serving as the Chairpersons or Vice Chairpersons, as applicable, of the Board or such committees in 2021. Our non-employee directors on the Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee also each received an annual retainer of $10,000, $5,000 and $7,500, respectively, for serving on such committees in 2021. The Board and committee annual retainers are payable on a quarterly basis at the end of each quarter. Our non-employee directors were also reimbursed for their expenses in attending Board and committee meetings in 2021.

Additionally, during March, June and July of 2021, Messrs. Brooks, Reid and Levin each received retainer fees of $10,000 per month for their service on a Special Committee of the Board. Ms. Lody also served on such Special Committee during 2021, but did not receive any compensation in respect of such service.

Report of the Audit Committee

The Audit Committee oversees the Company’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the audited financial statements in the Annual Report on Form 10-K with management, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements.

The Audit Committee reviewed with the independent auditors, who are responsible for expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of the Company’s accounting principles and such other matters as are required to be discussed with the Audit Committee under generally accepted auditing standards. The Audit Committee also discussed with the independent auditors the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the SEC. The Company’s independent auditors also provided to the Audit Committee the written disclosures and the letter required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant’s communications with the Audit Committee concerning independence, and the Audit Committee discussed with the independent auditors their independence and the compatibility of non-audit services with such independence.

The Audit Committee discussed with the independent auditors the overall scope and plans for their respective audits. The Audit Committee meets with the independent auditors, with and without management present, to discuss the results of their examinations, their evaluations of the Company’s internal controls, and the overall quality of the Company’s financial reporting.

In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the Board of Directors has approved) that the audited financial statements be included in the Annual Report on Form 10-K for the year ended December 31, 2021 for filing with the SEC.

Audit Committee

JILL M. KRUEGER, CHAIRPERSON

PHILIP A. BROOKS

BENJAMIN P. HARRIS

DAVID W. JOHNSON

CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

Policy of the Board of Directors

The Board has adopted a statement of policy with respect to transactions involving us and “related persons” (generally our senior officers, directors, nominees for director, persons owning five percent or more of our outstanding common stock, immediate family members of any of the foregoing, or any entity which is owned or controlled by any of the foregoing persons or an entity in which any of the foregoing persons has a substantial ownership interest or control). The policy generally covers any related person transaction involving amounts greater than $25,000 in which a related person has a direct or indirect material interest.

Under the policy, each related person transaction must be entered into on terms that are comparable to those that could be obtained as a result of arm’s length dealings with an unrelated third party and must be approved by the Audit Committee. Pursuant to the policy, at the first regularly scheduled meeting of the Audit Committee each calendar year, members of our management will recommend related person transactions to be entered into by us for that year, including the proposed aggregate value of any such transaction. After review, the Audit Committee will approve or disapprove each such related person transaction. No member of the Audit Committee will participate in any discussion or approval of a related person transaction for which he or she is a related person, except that such member will provide all material information concerning the related person transaction. At each subsequently scheduled meeting of the Audit Committee, members of our management will update the Audit Committee as to any material change with respect to each approved related person transaction.

In the event that our management recommends any further related person transactions subsequent to the first meeting of the Audit Committee in a particular calendar year, such transactions may be presented to the Audit Committee for approval or disapproval, or preliminarily entered into by members of our management subject to ratification by the Audit Committee. However, if the Audit Committee ultimately declines to ratify any such related person transaction, our management will make all reasonable efforts to cancel or annul the transaction.

PROPOSAL TO RATIFY APPOINTMENT OF INDEPENDENT AUDITORS

(PROPOSAL 2)

The Audit Committee has appointed RSM US LLP (“RSM”), independent auditors, to be our principal independent auditors and to audit our consolidated financial statements for the fiscal year ending December 31, 2022. Ernst & Young LLP (“Ernst & Young”) served as our independent registered public accounting firm for the fiscal year ended December 31, 2021.

Representatives of RSM and Ernst & Young are expected to be present at the Annual Meeting and will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

The Audit Committee has the responsibility for the selection of our independent auditors. Although stockholder ratification is not required for the selection of RSM, and although such ratification will not obligate us to continue the services of such firm, the Board is submitting the selection for ratification with a view towards soliciting our stockholders’ opinion thereon, which may be taken into consideration in future deliberations. If the appointment is not ratified, the Audit Committee must then determine whether to appoint other auditors before the end of the current fiscal year and, in such case, our stockholders’ opinions would be taken into consideration.

The Board of Directors unanimously recommends a vote “FOR” the ratification of RSM US LLP as our independent auditors for the fiscal year ending December 31, 2022.

Change in Independent Registered Public Accounting Firm

As previously reported in the Company’s Current Report on Form 8-K filed with the SEC on April 19, 2022, on April 13, 2022 and following a competitive request for proposals process, the Audit Committee approved the engagement of RSM, effective April 17, 2022, as its independent registered public accounting firm for the fiscal year ending December 31, 2022. On April 13, 2022, the Audit Committee also approved the dismissal of Ernst & Young as independent registered public accounting firm of the Company effective April 16, 2022.

The reports of Ernst & Young on the Company’s financial statements as of and for the fiscal years ended December 31, 2021 and 2020 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that Ernst & Young’s report dated March 31, 2021 contained an explanatory paragraph regarding the Company stating there was substantial doubt about the Company’s ability to continue as a going concern.

During the fiscal years ended December 31, 2021 and 2020, and in the subsequent interim period through April 16, 2022: (i) there were no disagreements (as defined in Item 304(a)(iv) of Regulation S-K and the related instructions) with Ernst & Young on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of Ernst & Young, would have caused Ernst & Young to make reference to the matter in its report and (ii) except for the matters referenced below, there were no reportable events (as defined in Item 304(a)(v) of Regulation S-X and the related instructions).

As disclosed in Item 9A of each of the Company’s Annual Reports on Form 10-K as of and for the fiscal years ended December 31, 2021 and 2020, the Company identified a material weakness in its internal control over financial reporting. This reportable event was discussed between the Audit Committee and Ernst & Young, and Ernst & Young has been authorized by the Company to respond fully to the inquiries of RSM, the successor independent registered public accounting firm of the Company, concerning this reportable event.

During the fiscal years ended December 31, 2021 and 2020 and the subsequent interim period through April 16, 2022, neither the Company nor anyone acting on the Company’s behalf consulted RSM regarding:

(i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that RSM concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions).

FEES PAID TO INDEPENDENT AUDITORS

The aggregate fees billed by the Company’s independent registered public accounting firm for fiscal years 2021 and 2020 were as follows:

Services Rendered

  2021   2020 

Audit fees(1)

  $1,481,000   $920,330 

Audit-Related fees(2)

       87,130 

Tax fees(3)

        

All other fees

        
  

 

 

   

 

 

 

Total

  $1,481,000   $1,007,460 
  

 

 

   

 

 

 

(1)

Includes professional services for the audit of our annual financial statements, reviews of the financial statements included in our Form 10-Q filings, and services that are normally provided in connection with statutory and regulatory filings or engagements.

(2)

Includes fees associated with assurance and related services that are reasonably related to the performance of the audit or review of our financial statements.

(3)

Includes fees associated with tax compliance, tax advice and tax planning.

The Audit Committee has considered whether the provision of the above services other than audit services is compatible with maintaining the independence of the Company’s independent registered public accounting firm and has concluded that it is.

Audit Committee Pre-Approval of Services Performed by Independent Auditors

The Audit Committee has the sole authority to appoint or replace the independent auditor and is directly responsible for the compensation and oversight of the work of the independent auditor. The Audit Committee is responsible for the engagement of the independent auditor to provide permissible non-audit services, which require pre-approval by the Audit Committee (other than with respect to de minimis exceptions described in the rules of the NYSE or the SEC that are approved by the Audit Committee).

ADVISORY VOTE ON EXECUTIVE COMPENSATION

(PROPOSAL 3)

We are submitting an Advisory Vote on Compensation to our stockholders. For more information about our executive compensation objectives and practices, please see “Compensation of Executive Officers” above.

We seek to maintain high standards with respect to the governance of executive compensation. Key features of our executive compensation policies and practices that aim to drive performance and align with stockholder interests are highlighted below:

Our Compensation Practices

(What we do)

Our Prohibited Compensation Practices

(What we don’t do)

✓  Align Pay with Performance: A significant portion of officer compensation is at risk and earned through short- and long-term incentives to align pay outcomes with company performance objectives and shareholder value creation.

✓  Double Trigger Vesting: We provide for double-trigger cash severance and equity vesting for termination of employment following a change-of-control.

✓  Robust Stock Ownership Guidelines: We have Stock Ownership Guidelines for both executives and directors.

✓  Clawback Policy: Our named executive officers are subject to a robust recoupment policy that applies to cash and equity-based incentive compensation in the event the Company is required to restate its financial statements.

✓  Annual Review: We conduct an annual review of our executive compensation program to ensure it rewards executives for strong performance, aligns with stockholder interests, retains top talent, and discourages unnecessary risk taking by our executives.

✓  Caps on Incentive Payout: We cap incentive payouts for each named executive officer at a specified percentage of base pay for such officer.

×   No Guaranteed Increases: We do not guarantee salary increases or annual incentives for our named executive officers.

×   No Hedging: We prohibit the hedging of the Company’s stock by directors, officers, or employees of the Company.

×   No Pledging: We prohibit the pledging of the Company’s stock by directors and officers of the Company.

×   No Repricing Without Stockholder Approval: We do not reprice underwater stock options without stockholder approval.

×   No Discount Grants: We do not provide for grants of equity below fair market value.

×   No Excessive Perquisites or Special Benefits: Our named executive officers are only eligible to participant in benefit plans that are generally available to all of our employees.

×   No Excise Tax Gross-Ups: We do not provide any gross-up payments for so called “golden parachute” payments in the event of a change in control.

✓  Shareholder Engagement: We engage with our shareholders regarding their most-important compensation concerns, and, as described herein, implement practices to address such concerns.

Our Compensation Practices

(What we do)

Our Prohibited Compensation Practices

(What we don’t do)

✓  Independent Consultant: We use an independent compensation consultant retained by the Compensation Committee, in its sole discretion, who performs no consulting or other services for the Company’s management.

The following key objectives are the cornerstone of our executive compensation program:

establish competitive target pay in line with those with whom we compete for executive-level talent;

retain talented individuals;

designs revolving around a strong link between executive pay and Company performance;

prudent risk taking by executives;

aligning our goals, efforts and results through a comprehensive executive compensation design, process and overall package; and

continually engaging stockholders in the overall process.

We believe these objectives collectively link compensation to overall Company performance and directly link compensation to the objectives set forth in our 2021 business plan that was developed with our BoardCertificate of Directors. These objectives help ensure that the interests of our named executive officers are closely aligned with the interests of our stockholders.

Incorporation. The vote on this resolution is not intended to address any specific element of compensation, but rather relates to the compensation of our named executive officers, as described in this Proxy Statement in accordance with the compensation disclosure ruleschairman of the SEC. The vote is advisory, which means thatmeeting may disregard the introduction of any such proposal or nomination if it is not binding on us, our Boardmade in compliance with the foregoing procedures or the Compensation Committee. The SEC rules adopted in response to the matters pertaining to executive compensation in the Dodd-Frank Act did not specify a voting standard for this proposal. As a result, pursuant to our Bylaws, assuming the presence of a quorum, the affirmative vote of the holders of a majority of the outstanding sharesapplicable provisions of our common stock entitled to vote, present in person or represented by proxy, at the Annual Meeting is required to approve, on an advisory basis, this Proposal 3.Certificate of Incorporation.

Accordingly, we ask our stockholders to vote on the following resolution at the Annual Meeting:

RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby APPROVED.”

The Board of Directors unanimously recommends a vote “FOR” the approval of the compensation of our named executive officers, as disclosed in this Proxy Statement.

OTHER BUSINESS

(PROPOSAL 4)

The Board of Directors knows of no other business to be brought before the Annual Meeting. If, however, any other business should properly come before the Annual Meeting, the persons named in the proxy will vote the proxy in their discretion as they may deem appropriate, unless directed by the proxy to do otherwise.

GENERAL

The cost of any solicitation of proxies will be borne exclusively by us. Arrangements may be made with brokerage firms and other custodians, nominees and fiduciaries for the forwarding of material to and solicitation of proxies from the beneficial owners of shares of our stock held of record by such persons, and we will reimburse such brokerage firms, custodians, nominees and fiduciaries for reasonable out of pocket expenses incurred by them in connection therewith. Brokerage houses and other custodians, nominees and fiduciaries, in connection with shares of our stock registered in their names, will be requested to forward solicitation material to the beneficial owners of such shares and to secure their voting instructions. We have retained Georgeson to assist in soliciting proxies for the AnnualSpecial Meeting for a fee of $8,500.$8,500 plus expenses and out-of-pocket costs. The cost of such solicitation will be borne exclusively by us.

By Order of the Board of Directors

 

LOGO

  

LOGO

LOGO

David W. Johnson

Chairman of the Board

  

Kimberly S. Lody

Brandon M. Ribar

President and Chief Executive Officer

April 29, 2022February [●], 2024

Addison,Dallas, Texas

13


LOGOAnnex A

Certificate of Amendment

to the

Certificate of Incorporation

[See attached]


SIXTH CERTIFICATE OF AMENDMENT

TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED,

OF

SONIDA SENIOR LIVING, INC.

Sonida Senior Living, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

FIRST: That the Board of Directors of the Corporation duly adopted resolutions proposing and declaring advisable the following amendments to the Corporation’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”):

The first sentence of the FOURTH Article of the Certificate of Incorporation is hereby amended and restated by deleting such sentence in its entirety and replacing it with the following sentence:

“FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is 30,000,000 shares of common stock, at a par value of $0.01 per share (“Common Stock”), and 15,000,000 shares of preferred stock, at a par value of $0.01 per share (“Preferred Stock”).”

SECOND: That the foregoing amendment was duly adopted by the Corporation’s Board of Directors and stockholders in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.

THIRD: All other provisions of the Certificate of Incorporation shall remain in full force and effect.

IN WITNESS WHEREOF, this Sixth Certificate of Amendment has been duly executed as of the [●] day of [●] 2024.

SONIDA SENIOR LIVING, INC.

By:

Name:

Brandon M. Ribar

Title:

President and Chief Executive Officer

A-1


LOGO

 

Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. LOGO  

 

 
AnnualSpecial Meeting Proxy Card

LOGO IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.LOGO

 

 

 

LOGO

 A 

 

 

Proposals – The Board of Directors recommends a vote FOR Proposals 1 2, 3 and 42

 

1. Proposal to elect as directors of the Company the following persons to hold office until the annual meeting of stockholders of the Company to be held in 2025, or until their respective successors are duly qualified and elected.

LOGO

 

 01 - Philip A. Brooks02 - Benjamin P. Harris03 - David W. Johnson
Mark here to vote
FOR all nominees
Mark here to WITHHOLD
vote from all nominees

For All EXCEPT - To withhold authority to vote for any nominee(s),

write the name(s) of such nominee(s) below.

 For Against Abstain 

2.1. Proposal to ratify the Audit Committee’s appointment of RSM US LLP, independent accountants, asapprove an amendment to the Company’s independent auditors forAmended and Restated Certificate of Incorporation, as amended, to increase the fiscal year ending December 31, 2022.number of authorized shares of common stock from 15,000,000 shares to 30,000,000 shares.

    

This proxy will be voted as directed herein by the undersigned stockholder. If no direction is made, this proxy will be voted as indicated below:

“FOR” the election of each of the nominees for director (Proposal 1) and “FOR” Proposals 2, 31 and 4.

2.
 
 For Against Abstain 

3.2. Proposal to approve the Company’s executive compensation.adjournment of the Special Meeting to solicit additional proxies if there are insufficient proxies at the Special Meeting to approve the foregoing proposal.

    PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.
   
 ForAgainst

Abstb

ain

4. In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting.

 

 

 B 

Authorized Signatures – This section must be completed for your vote to be counted. – Date and Sign Below

LOGONOTE: Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such.

03MM8E

Date (mm/dd/yyyy) - Please print date below.

Signature 1 - Please keep signature within the box.

Signature 2 - Please keep signature within the box.

  /  /

LOGO


 

 

LOGO IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.LOGO

 

 

 

 
 Proxy – Sonida Senior Living, Inc. LOGO

16301 Quorum Drive,14755 Preston Road, Suite 160A810

Addison, TX 75001Dallas, Texas 75254

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned hereby appoints Kimberly S. LodyBrandon M. Ribar and David R. Brickman, and each of them, as proxies, each with the power to appoint her or his substitute, and hereby authorizes them to represent and vote, as designated hereon, all the shares of the common stock and Series A Convertible Preferred Stock of Sonida Senior Living, Inc. (the “Company”), held of record by the undersigned on April 18, 2022,February 12, 2024, at the AnnualSpecial Meeting of Stockholders of the Company to be held at the RenaissanceCompany’s Corporate Office at 14755 Preston Road, Suite 810, Dallas, Texas 75254 on March 21, 2024 at Plano Legacy West Hotel, Tokyo Conference Room, at 6007 Legacy Drive, Plano, Texas 75204 on June 9, 2022 at 9:3:00 AMPM Central Time, and any postponement(s) or adjournment(s) thereof.

IT IS IMPORTANT THAT PROXIES BE RETURNED PROMPTLY. STOCKHOLDERS WHO DO NOT EXPECT TO ATTEND THE MEETING AND WISH FOR THEIR STOCK TO BE VOTED ARE URGED TO DATE, SIGN AND RETURN THE ACCOMPANYING PROXY IN THE ENCLOSED SELF-ADDRESSED ENVELOPE. NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED STATES.

(Continued and to be marked, dated and signed, on the other side)

 

 B 

Authorized Signatures – This section must be completed for your vote to be counted. – Date and Sign Below

NOTE: Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such.

Date (mm/dd/yyyy) – Please print date below.Signature 1 – Please keep signature within the box.Signature 2 – Please keep signature within the box.
            /            /             

 

 C 

 

 

Non-Voting Items

 

 

Change of Address – Please print new address below.

  

Comments – Please print your comments below.

  

 

LOGO    LOGO